Summer 2004 • Volume 9, Issue 2 THE MDS NEWS · Summer 2004 • Volume 9, Issue 2 The Newsletter...
32
THE MDS NEWS Summer 2004 • Volume 9, Issue 2 The Newsletter of The Myelodysplastic Syndromes Foundation From the Guest Editor’s Desk David T. Bowen, MD University of Dundee Medical School Dundee, Scotland WHAT CAUSES MDS? Introduction Amongst the most frequent questions asked by patients soon after the diagnosis of MDS are: “Why me?” “What causes MDS?” “Could I have done anything different to avoid getting MDS?” and “Can my children get it?” The simple answer to these questions is that for the vast majority of patients, we have few clues as to the cause of their MDS. The study of the causes of these diseases is proving difficult for the following reasons: 1. MDS is more than one disease 2. Few comprehensive patient registries exist to accurately determine who gets the different subtypes of MDS (e.g. age/sex distribution) 3. Determining the length of time to develop MDS is difficult More Than One Disease The diagnostic process involves categorising an individual’s disease into one of five French-American- British (FAB) groups or one of six World Health Organisation (WHO) subgroups (the latter excluding sub-types CMML and the old RAEB-t). These classification systems recognise the differences in the bone marrow appearance and the chromosome abnormalities within the different subgroups of MDS. It does not therefore require a large leap of faith to expect that diseases that look different down a microscope (albeit with certain overlapping similarities), might have different causes. Attempts to study the cause of MDS (“epidemiology”) have focussed mainly on case-control studies, consisting of questionnaires requesting information about the work and recreational background of MDS patients, compared with a “control” group of individuals who do not have MDS. Whilst these efforts are commendable, and the best that can be achieved, there are many limitations to such studies. These include “recall bias”, relying on the patient’s memory for accuracy, and size of the patient group studied, which in turn determines the “power” of the study, and hence the confidence that the results are truly accurate and not simply statistical chance. For the purposes of most of these studies, MDS has been considered as one disease, given that the numbers in each subgroup will be small. Who Gets MDS? MDS is a rare disease, whose incidence is 4 per 100,000. The disease becomes more common with increasing age, such that the incidence rises to >30 per 100,000 for people over 70 years of age. Males are more commonly affected than females, although there is some evidence that this is not so for Refractory Anemia with Ring Sideroblasts (RARS) (Dr. U. Germing, personal communication). Contents MDS Awareness Year 4 FDA Approves Pharmion’s Vidaza 5 PBS Presents 5 Response to TRISENOX ® in MDS 6 A Living Endowment 11 Blood & Marrow Transplant News 11 MDS Membership Information 11 8th International Symposium in Japan 12 About the Foundation 13 MDS Patient Registry 13 MDS Centers of Excellence 14 MDS Educational Resources 15 Patient Referrals 15 International Clinical Trials: An Update 16 Be a Bone Marrow Donor 27 MDS Foundation Golf Tournament 27 In Memorium 28 Patient Services 30 Gifts to the Foundation 32 MDS Board of Directors 32 (continued on page 2)
Transcript of Summer 2004 • Volume 9, Issue 2 THE MDS NEWS · Summer 2004 • Volume 9, Issue 2 The Newsletter...
THE MDS NEWSSummer 2004 • Volume 9, Issue 2
The Newsletter of The Myelodysplastic Syndromes Foundation
From the GuestEditor’s DeskDavid T. Bowen, MDUniversity of Dundee Medical SchoolDundee, Scotland
WHAT CAUSES MDS?
Introduction
Amongst the most frequent questions asked bypatients soon after the diagnosis of MDS are:
“Why me?”
“What causes MDS?”
“Could I have done anything different to avoid getting MDS?” and “Can my children get it?”
The simple answer to these questions is that for thevast majority of patients, we have few clues as tothe cause of their MDS.
The study of the causes of these diseases is provingdifficult for the following reasons:
1. MDS is more than one disease
2. Few comprehensive patient registries exist toaccurately determine who gets the differentsubtypes of MDS (e.g. age/sex distribution)
3. Determining the length of time to develop MDS is difficult
More Than One Disease
The diagnostic process involves categorising anindividual’s disease into one of five French-American-British (FAB) groups or one of six World HealthOrganisation (WHO) subgroups (the latter excludingsub-types CMML and the old RAEB-t). Theseclassification systems recognise the differences inthe bone marrow appearance and the chromosomeabnormalities within the different subgroups of MDS.It does not therefore require a large leap of faith toexpect that diseases that look different down amicroscope (albeit with certain overlappingsimilarities), might have different causes.
Attempts to study the cause of MDS (“epidemiology”)have focussed mainly on case-control studies,consisting of questionnaires requesting informationabout the work and recreational background ofMDS patients, compared with a “control” group ofindividuals who do not have MDS. Whilst theseefforts are commendable, and the best that can beachieved, there are many limitations to such studies.These include “recall bias”, relying on the patient’smemory for accuracy, and size of the patient groupstudied, which in turn determines the “power” of thestudy, and hence the confidence that the results aretruly accurate and not simply statistical chance. Forthe purposes of most of these studies, MDS hasbeen considered as one disease, given that thenumbers in each subgroup will be small.
Who Gets MDS?
MDS is a rare disease, whose incidence is 4 per100,000. The disease becomes more common withincreasing age, such that the incidence rises to>30 per 100,000 for people over 70 years of age.Males are more commonly affected than females,although there is some evidence that this is notso for Refractory Anemia with Ring Sideroblasts(RARS) (Dr. U. Germing, personal communication).
ContentsMDS Awareness Year 4FDA Approves Pharmion’s Vidaza 5PBS Presents 5Response to TRISENOX® in MDS 6A Living Endowment 11Blood & Marrow Transplant News 11MDS Membership Information 118th International Symposium in Japan 12About the Foundation 13MDS Patient Registry 13MDS Centers of Excellence 14MDS Educational Resources 15Patient Referrals 15International Clinical Trials: An Update 16Be a Bone Marrow Donor 27MDS Foundation Golf Tournament 27In Memorium 28Patient Services 30Gifts to the Foundation 32MDS Board of Directors 32 (continued on page 2)
2
MDS in children is more infrequent still, and hasdifferent characteristics to the adult form. Examplesof these differences include the spectrum of FAB/WHOtypes (RARS and 5q- syndrome are almost neverseen in childhood), and of chromosome abnormalities(a higher proportion of children have abnormalitiesof chromosome 7).
MDS may also evolve from related disorders such as Aplastic Anemia (following immuno-suppression treatment) or Paroxysmal NocturnalHaemoglobinuria (PNH).
How Long Does it Take to Develop MDS?For patients with de novo MDS, the latency time todisease development is unknown. From a biologicalangle, there will be at least two phases of diseasedevelopment, namely 1) the time from the firstdamage in the bone marrow to the appearance of achange in the blood count, then 2) the time from thefirst blood count abnormality to the presentationwith clinically relevant disease (usually symptomsof anaemia) (Figure 1). Both are impossible to studysystematically at present.
For cases of MDS developing after exposure to anagent known or presumed to cause MDS, thelatency period varies. This may be from 1–41 yearsfor different radiation exposures,1 1–10 years foralkylator cytotoxic drugs,2,3 and more difficult toassess (but up to 30 years?) for benzene.4
cytotoxic drugs are implicated, but alkylators mostfrequently cause an MDS phase. One of the majorchallenges in the treatment of highly curable diseasessuch as Hodgkin’s lymphoma is now to reduce therisk of late complications, and newer therapiesshould prove less likely to produce t-MDS/AML.
t-MDS/AML constitute <10% all cases of adult MDShowever, and the study of t-MDS/AML as a modelfor the causes of de novo MDS is problematic.Many cases of t-MDS cannot be easily classifieddue to bone marrow fibrosis (scarring). RARS andCMML are relatively under-represented, and thechromosome abnormalities in t-MDS/AML differ fromthose of the de novo diseases.3 Survival of patientswith t-MDS is also poorer than for de novo MDS.
Normal Bone Marrow Cell(+/– genetic predisposition)
Symptoms of MDS develop
Initiation of MDS
Latencyperiod
Transformation to AMLin some patients
EVENT(S) A
EVENT(S) B
EVENT(S) C
Established Causative Factors for MDS
Cytotoxic drugsTherapy-related MDS and AML (t-MDS/AML) arewell-recognised though rare complications followingcytotoxic drug therapy for malignant and some non-malignant (mainly autoimmune) diseases. The riskof developing t-MDS/AML following therapeuticradiotherapy remains less clear.5 Several classes of
Possible Causative Factors for MDS
RadiationMDS cases are reported in cohorts of peopleexposed to radiation, for treatment of diseases suchas ankylosing spondylitis, or following exposure tothe A-bomb in Hiroshima and Nagasaki. Some ofthese cases occurred up to 40 years after exposureand thus the precise association between thedevelopment of MDS and exposure to radiation isnot possible to quantify. Similarly, weak associationsbetween radiation exposure and MDS are identifiedin some (but not all) case-control epidemiology studies.
BenzeneLegislation now ensures that exposure to highconcentrations of benzene in the workplace or theenvironment should not occur. Thus, the main
Figure 1. Biological steps in the development of MDS
3
sources of exposure to low concentrations ofbenzene in daily life are tobacco smoke and petrol(cartoon). Tobacco smoking is a weak but consistentrisk factor (less than two-fold) for MDS in severalcase-control studies,6 but also contains many othercarcinogens in addition to benzene.
In contrast, exposure to high concentrations of benzeneclearly causes bone marrow toxicity, usually aplasia,some of which will progress to MDS and/or AML.7,8
MiscellaneousWhilst each individual published case-control studyhas identified a number of occupations andsubstances, which may be risk factors for MDS,there is little consistency between these studies. An exhaustive list of these possible risk factors istherefore not helpful, as many will represent statisticalchance or very weak relative risks.
The incidence of MDS increases with increasing age.This has been interpreted in two ways; the diseasemust result from a progressive accumulation of alifetime’s exposure to a toxic agent or, the agedbone marrow “stem” cell is easier to damage than itsyounger counterpart. The process of “ageing” is notwell defined, though much blame is heaped upon“free radicals”,9 defence against which deteriorateswith age. It remains unclear in what way this maybe relevant to diseases of older age such as MDS.
Is There an Inherited Tendency to Develop MDS?The vast majority of MDS patients presenting inadulthood have no relatives with the disease, andno obvious inherited disease with a tendency toMDS. 30% children with MDS have other associatedabnormalities, and some of these are part of well-recognised syndromes including Fanconi Anaemia,and Blooms Syndrome.
Families with several cases of MDS are described,but are exceptionally rare. Although still very rare,familial MDS may be more likely in the family of achild with monosomy 7.10 In the absence of otherfamily members with MDS, it is safe to confirm thatthe disease is vanishingly unlikely to run down thegenerations.
How Can We Study the Cause in the Future?A whole new avenue of research into the contributionof genetics to the cause of diseases, involves thestudy of natural variations in our DNA from person toperson. These variations can often lead to changesin the function of cells, and may therefore affect the
natural functions of a cell, such as neutralising toxicchemicals that enter the body. To date, no definitenatural variation in a gene has been associated withincreasing the risk of developing MDS, but this fieldis only in its infancy. Large numbers of patientsamples are needed for such studies, particularlyin MDS, where these large numbers are required foreach of the FAB/WHO groups.
This initiative requires the development of largeBiobanks, married to high-quality registries ofclinical and laboratory information cataloguing the characteristics of each patient’s disease.
CONCLUSIONDespite more than a decade of dedicated effort fromepidemiologists, clinicians and scientists, the causeof MDS remains largely unknown. It is inevitablethat the different subtypes of MDS will havedifferent causes. We must use the little high-qualitydemographic data (Who gets MDS?) to develophypotheses, and test these in a combination ofclinical and molecular epidemiology studies, whichby definition will need to involve very large patientnumbers. National and international collaborativeefforts are underway to attempt to achieve this.
REFERENCES01. Moloney WC. Radiogenic leukemia revisited. Blood.
1987;70:905–908.
02. Pedersen-Bjergaard J, Andersen MK, ChristiansenDH, Nerlov C. Genetic pathways in therapy-relatedmyelodysplasia and acute myeloid leukemia. Blood.2002;99:1909–1912.
03. Mauritzson N, Albin M, Rylander L et al. Pooledanalysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia andmyelodysplastic syndromes based on a consecutiveseries of 761 patients analyzed 1976–1993 and on5098 unselected cases reported in the literature1974–2001. Leukemia. 2002;16:2366–2378.
04. Voytek PE, Thorslund TW. Benzene risk assessment:status of quantifying the leukemogenic risk associatedwith the low-dose inhalation of benzene. Risk Anal.1991;11:355–357.
05. Andersen MK, Johansson B, Larsen SO, Pedersen-Bjergaard J. Chromosomal abnormalities insecondary MDS and AML. Relationship to drugs andradiation with specific emphasis on the balancedrearrangements. Haematologica. 1998;83:483–488.
06. Bjork J, Albin M, Mauritzson N et al. Smoking andmyelodysplastic syndromes. Epidemiology. 2000;11:285–291.
August 2004 Starts theMDS Awareness YearIn order to promote awareness and educationalinitiatives for the public and healthcare professionals,we are designating August as the inaugural monthfor a year dedicated to MDS Awareness. As part ofour outreach, we are planning a year-long awarenessand educational campaign. This year the Foundationhas expanded it’s outreach and participated in manynew events:
ASPH/O: April 29–30, 2004BIO 2004: June 6–9, 2004EHA: June 10–13, 2004NYC Patient Forum: August, 2004 (Date TBD)Inaugural Charity Golf Tournament: August 9, 2004ASH: December 4–7, 2004
4
07. Aksoy M, Dincol K, Erdem S, Dincol G. Acute leukemiadue to chronic exposure to benzene. Am J Med. 1972;52:160–166.
08. Rothman N, Smith MT, Hayes RB et al. Benzenepoisoning, a risk factor for haematological malignancy,is associated with the NQO1 609C->T mutation andrapid fractional excretion of chlorzoxazone. CancerResearch. 1997;57:2839–2842.
09. Kirkwood TB, Austad SN. Why do we age? Nature.2000;408:233–238.
10. Luna-Fineman S, Shannon KM, Lange BJ. Childhoodmonosomy 7: epidemiology, biology, and mechanisticimplications. Blood. 1995;85:1985–1999.
GLOSSARYEpidemiology: The study of frequency and cause ofdisease.
Incidence: The number of new cases presenting peryear in a given population.
Power (of a study): A calculation used in preparing astudy to determine whether the study is capable ofanswering the question asked. The power is determinedby the number of patients in the study and the size ofthe effect that the researchers expect to see and wouldconsider to be medically important.
Case-control study: A widely used epidemiologymethod for studying cause of disease. A group ofpatients (“cases”) are compared with a matched groupof individuals lacking the disease (usually healthy),“controls”.
Relative risk: The numerical chances of developing adisease in a given set of circumstances. In this contextthe chance of developing MDS if you are exposed tochemical x, or have genetic tendency y. Relative risk of2=two-fold, 4=four-fold etc.
Latency: In this context, the “lag” time from the firstevent that might start the disease process to the timethe disease presents to a doctor.
De novo: Disease presenting with no obvious factorsknown to cause the disease.
Celgene has provided the MDS Foundation with unrestrictededucational grants to support the Foundation’s work.
April 04: The MDS Foundation’s Susan Hogan and Nancy Mrzljakpromoted MDS Awareness at The American Society of PediatricHematology/Oncology Meeting in San Francisco, CA.
June 04: Kathy Heptinstall and Nancy Mrzljak provided attendeesat EHA, Geneva, Switzerland, with up-to-date information fromthe Foundation.
5
First Drug Approved for theTreatment of MDS
May 19, 2004: Pharmion Corporation todayannounced that it has received full approval fromthe U.S. Food and Drug Administration (FDA) tomarket Vidaza for the treatment of MyelodysplasticSyndromes (MDS). The FDA approved Vidaza fortreatment of all five MDS subtypes. These subtypesinclude: refractory anemia (RA) or refractory anemiawith ringed sideroblasts (RARS) (if accompanied byneutropenia or thrombo-cytopenia or requiringtransfusions), refractory anemia with excess blasts(RAEB), refractory anemia with excess blasts intransformation (RAEB-T), and chronic myelomonocyticleukemia (CMMoL). Pharmion intends to makeVidaza commercially available within several weeks.
“The approval of Vidaza represents a significantmilestone for Pharmion and, more importantly,represents an important new option for patientsbeing treated for Myelodysplastic Syndromes,” saidPatrick J. Mahaffy, president and chief executiveofficer of Pharmion. “Until today, there have beenno approved therapies for the treatment of MDS.We are proud to have advanced the work of theNational Cancer Institute, the Cancer and LeukemiaGroup B (CALGB) and other academic institutionsand clinicians to the point that this drug can now becommercially available to treat this very serious andlife-threatening disease.”
Vidaza is believed to exert its anticancer effects bycausing demethylation, or hypomethylation, of DNAin abnormal blood-forming (hematopoietic) cellsin the bone marrow as well as through its directcytotoxic effect. Demethylation may restore normal
Pharmion has provided the MDS Foundation with unrestrictededucational grants to support the Foundation’s work.
PBS PresentsA new series on PBS, Healthy Body,Healthy Mind, offers a segment devoted to MDS and the MDS Foundation. Pleasecheck your local listing for this specialsegment of this new series.
The Foundation offers its special thanks for Celgene’s support of a new health and wellness TV series, Healthy Body,Healthy Mind.
For a VHS copy of a 30-minute documentary style program of “MDS”call 1-800-MDS-0839.
Share Your StoriesWith The MDSCommunityThe Foundation would like to invite patients andtheir families to share their stories with others in the MDS community. Living with MDS poseschallenges and many of you have stories thatprovide hope to others.
Please contact the Foundation if you would like us to publish your story!!!
function to tumor-suppressor genes which areresponsible for regulating cell differentiation andgrowth. The cytotoxic effects of azacitidine causethe death of rapidly-dividing cells, including cancercells that are no longer responsive to normal growthcontrol mechanisms. Non-proliferating cells arerelatively insensitive to Vidaza.
For more information or complete prescribinginformation about Vidaza, please call 1-866-PHARMION, or view full prescribing informationonline at www.pharmion.com.
FDA Approves Pharmion’s Vidaza™
for the Treatment of MDS
6
Response toTRISENOX® Therapyin MDS PatientsResponses Seen in High-Risk and Low-Risk Patients
In EuropePreliminary data from a phase II clinical trial ofTRISENOX® (arsenic trioxide) injection in patientswith myelodysplastic syndromes (MDS) were presentedat the 9th Congress of the European HematologyAssociation (EHA), held in Geneva, Switzerland.The multicenter European study, led by Norbert Vey,MD, of Institut Paoli-Calmettes, Marseille, France,was conducted in high-risk and low-risk MDSpatients; the study findings showed that arsenictrioxide, administered as a single-agent, produced ahematologic response in 27% of study participants.
“These results establish the clinical activity of arsenictrioxide in MDS. Most notable was the high numberof patients achieving transfusion independence.Given this positive activity in both low- and high-riskMDS patients and the good safety profile, TRISENOX®
is a prime candidate to investigate in combinationtherapy,” stated Vey.
The objectives of the study were to determine thesafety and efficacy of arsenic trioxide as a singleagent in patients with low-risk and high-risk disease.(Low-risk patients were defined as those with low orintermediate-1 MDS according to the InternationalPrognostic Scoring System, or IPSS, disease riskclassification; high-risk patients were defined asthose with intermediate-2 or high MDS according toIPSS.) Arsenic trioxide was administered at a doseof 0.3 mg/kg per dose for 5 days during the firstweek (loading dose), followed by 0.25 mg/kg perday twice weekly (maintenance dose).
Treatment responses were observed across allhematologic lineages in high-risk patients andincluded one complete response. In low-risk patients,responses were seen in two lineages: no neutrophilresponses were observed. Of the 39 patients withlow-risk MDS, 9 achieved responses (23%), including5 patients with major responses (13%). Of the 62high-risk MDS patients, 18 achieved responses(29%), and 16 of those were major responses (26%).The duration of response was approximately 4months (median); however, the true duration of
response is not yet known because 20 of 27 patientswere still in the response phase at the time of thelast assessment.
Of the 83 patients who were dependent on red bloodcell transfusions at the start of the study, 16 (19%)became transfusion independent or had a 50% orgreater decrease in transfusion requirements. Similarly,5 of 38 patients (13%) who were dependent on platelettransfusions became transfusion independent or hada 50% or greater decrease in transfusion requirements.
Arsenic trioxide was generally well tolerated in thisstudy, with most treatment-related adverse eventsmild to moderate in intensity and manageable. Only3 patients experienced serious (grade 4) thrombo-cytopenia, neutropenia, or pulmonary edema.
Dr. Vey’s team concluded that the outpatient arsenictrioxide regimen evaluated in their study is safe,tolerable, and biologically active in MDS patients.
About TRISENOX®
(Arsenic Trioxide)
TRISENOX®, the brand name of the injectablesolution of arsenic trioxide, was approved in2000 by the U.S. Food and Drug Administration(FDA) for the treatment of relapsed or refractoryacute prolmyelocytic leukemia (APL), a rare, life-threatening hematologic malignancy. APL isone of eight subtypes of acute myeloid leukemia(AML), and represents 10 to 15% of the morethan 20,000 patients diagnosed with AMLeach year. TRISENOX® was granted marketingauthorization from the European Commission inMarch 2002.
TRISENOX® may exert its antitumor effects via theinduction of programmed cell death (apoptosis)and/or the inhibition of new blood vessel growthto neoplastic tissue (antiangiogenesis). Althoughcurrently indicated for relapsed and refractoryAPL, TRISENOX® has also demonstrated favorableclinical results as an effective treatment for MDSas a single-agent therapy and in combinationwith thalidomide. TRISENOX® has been grantedOrphan Drug Designation by the FDA for thetreatment of MDS. TRISENOX® is also listed inthe 2004 USP DI Volume III Approved DrugProducts and Legal Requirements for MDS.TRISENOX® is currently being studied in morethan 40 clinical trials in a variety of cancers andhematologic conditions.
7
REFERENCE
1. Vey N, Dreyfus F, Guerci A, et al. Trisenox® (arsenictrioxide) in patients with myelodysplastic syndromes(MDS): preliminary results of a phase I/II study. In:Abstracts and Program of the 9th Congress of theEuropean Hematology Association, June 10–13, 2004,Geneva, Switzerland. Abstract #467.
In the United StatesA phase II clinical trial conducted at several sites inthe U.S. also examined arsenic trioxide as a single-agent therapy in low-risk and high-risk MDS patients.Alan List, MD, of the H. Lee Moffitt Cancer Centerand Research Institute in Tampa, Florida, andcolleagues reported the study’s findings at the 40thannual meeting of the American Society of ClinicalOncology in New Orleans, Louisiana in June. Of the62 evaluable patients who received arsenic trioxidefor approximately 4 months, 12 (19%) had responses,and 10 of these (16%) were major responses.
When the responses were examined by disease risk,major responses were seen in high- and low-riskpatients. Of the 29 low-risk patients, 8 (28%) achievedresponses, 6 of which were major responses (21%).Of the 33 high-risk patients, 4 (12%) achievedresponses, and all of these were major responses.The median duration of response was 4.2 monthsfor erythroid responses, 5.9 months for neutrophilresponses, and 4.0 months for platelet responses.
Treatment consisted of arsenic trioxide, given as anintravenous infusion at a dose of 0.25 mg/kg over 1to 2 hours per day on days 1 to 5 and on days 8 to12 every 28 days. (See Figure 1 for European vs.U.S. treatment regimens. Note that currently theEuropean regimen is the most widely regimen usedin clinical studies.)
As in the European study, the effect of arsenictrioxide treatment on transfusion dependence wasencouraging. Of the 32 patients who were dependenton red blood cell transfusions at the start of thestudy, 5 (16%) achieved transfusion independence,and 1 of 7 (14%) patients who were dependent onplatelet transfusions became transfusion independent.
One of the study authors, Dan Douer, MD, of theUniversity of California/Norris Cancer Center in Los Angeles, commented on the impact of arsenictrioxide treatment: “TRISENOX® has been shown toincrease the number of red cells as well as the twoother blood cell types in MDS patients. The fact that several responding patients no longer requiredtransfusions is very significant. Responses were seen
not only in low-risk but also in the sicker, high-riskpatients who often need more transfusions and aremore difficult to treat.”
Treatment with arsenic trioxide was generally welltolerated in this study, with most treatment-relatedadverse events of mild to moderate intensity. Severe(grade 4) toxicities included neutropenia, leukopenia,and thrombocytopenia in a limited number of patients.
REFERENCE
1. List AF, Schiller GJ, Mason J, et al. Arsenic trioxide inpatients with myelodysplastic syndromes (MDS):preliminary results of a phase II clinical study. In:Abstracts and Program of the 40th Annual Meeting ofthe American Society of Clinical Oncology, June 5–8,2004, New Orleans, LA. Abstract #6512.
Arsenic Trioxide in Combinationwith ThalidomideIn addition to studies of its use as a single-agenttherapy, arsenic trioxide has demonstrated clinicalefficacy in MDS when combined with otherchemotherapeutic agents. A recently published pilotstudy in 28 MDS patients (25 patients with primaryMDS, 3 patients with secondary MDS) evaluatedarsenic trioxide and low-dose thalidomide as acombination therapy regimen. The study hypothesiswas that this “2-pronged” approach would provideadditional benefits compared with single-agentarsenic trioxide therapy because of the distinctmechanisms of action of each component of thecombination regimen. Indeed, 25% of the studyparticipants had a multi-lineage response followingtreatment with arsenic trioxide and thalidomide.
Seven patients achieved responses, including 1complete remission (hematologic and cytogeneticresponse); see Table 1. The duration of the
Figure 1. Dosing Regimens ofArsenic Trioxide in MDS Patients
US Regimen
TRISENOX® (arsenic trioxide) 0.25 mg/kg (10 doses/2 wk),5 days/wk for 2 wk followed by no dosing for 2 wk
TRISENOX® 0.30 mg/kg for 5 days and 0.25 mg/kg twice weekly for an additional 15 weeks
EU Regimen
1 2
Week 1
Loading
Week 2
3 4 5 8 9 10 11 12 14 2821
Week 3 Week 4 Week 16
8
responses, observed in high-risk and low-riskpatients, ranged from 2 to 9 months. Two tri-lineage responses were seen in patients withinv(3)(q21q26.2), a chromosome abnormality thatis associated with overexpression of the EVI1 gene.Patients with MDS or AML who have high levels ofEVI1 gene expression have been found to have apoor prognosis. Interestingly, in vitro studies haveshown EVI1-expressing cells to be particularlysensitive to arsenic trioxide. This clinical studydemonstrates that patients who express high EVI1may preferentially respond to this combinationtherapy. Although 5 of the 28 patients expressedhigh EVI1 levels at study entry, the finding that 2 ofthese patients achieved a tri-lineage response withthe combination therapy was surprising andencouraging. Furthermore, 1 of the 5 patients withhigh EVI1 levels had a minor erythroid response. Itshould be noted that patients who do not expresshigh levels of EVI1 also responded to arsenictrioxide/thalidomide combination therapy.
Table 1. Overall Response of Arsenic Trioxide andThalidomide Combination Therapy in MDS Patients
FAB Cytogenetics Response Duration, d———————————————————————————RARS 46XX HI-E minor 136
(50% PRBC)
RAEB 46XY inv(3)(q21q26.2) Trilineage 200
RAEB 46XY del(5)(q15q33) HI-E major(100% PRBC/Hgb) 280
RAEB 46XY HI-E major(100% PRBC/Hgb) 84
RAEB-t 45XY inv(3)(q21q26.2) Trilineage CR 293
RAEB-t 47XY, +8 HI-ANC, RAEB 63
Unclassified 46XY HI-E minor(50% PRBC) 107
——————————————————————————— FAB: French-American-British Classification of MDS Subtypes
REFERENCE
1. Raza A, Buonamici S, Lisak L, et al. Arsenic trioxideand thalidomide combination produces multi-lineagehematological responses in myelodysplastic syndromespatients, particularly in those with high pre-therapy EVI1expression. Leuk Res. 2004;28:791–803.
Safety Profile of Arsenic TrioxidePatient data from phase I and II studies, as well asfrom compassionate use programs andpostmarketing safety surveillance, have been usedto compile a safety and toxicity profile of arsenictrioxide. As of May 2004, arsenic trioxide has beenadministered to 804 patients in clinical trials (188MDS patients), and as of February 2004, anestimated 3135 patients in the U.S. and Europe(1277 MDS patients) have received arsenic trioxidein compassionate use programs or have beenincluded in postmarketing safety surveillance.
The postmarketing experience of arsenic trioxide hasshown that the drug-related side effects are generallysimilar to those observed in clinical trials. Importantly,postmarketing surveillance confirms that the adverse
Rationale for Use ofArsenic Trioxide in MDS
The pleiotropic effects of arsenic trioxide onthree distinct cellular pathways involved in thedevelopment of MDS—apoptosis, tumor celldifferentiation, and angiogenesis—make it anattractive therapy for this disease. Arsenictrioxide affects upstream and downstreamcomponents of the apoptotic response,inducing cell death by the abrogation ofcytokines necessary for the viability ofdysplastic cells and increasing thepermeability of the mitochondrial membrane,thus rendering the cells sensitive to apoptosis.Arsenic trioxide can also promote celldifferentiation through G1 cell cycle arrest, viap21 and p27 activation. Finally, arsenic trioxidepossesses anti-angiogenesis propertiesthrough the suppression of vascular endothelialgrowth factor (VEGF) in activated neovasculaturepresent in the bone marrow. Collectively, thediverse and significant in vitro activity of arsenictrioxide has driven the study of its use as apossible therapeutic agent for MDS in theclinical setting.
The combination therapy regimen was generally welltolerated, and combining the two chemotherapeuticagents did not exacerbate toxicities. Fluid retentionand myelosuppression were the major toxicities. All side effects were reversible upon treatmentdiscontinuation.
“Results of this combination study appear to bedifferent than the experience with thalidomide aloneas the responses from the combination regimen aremore commonly multi-lineage and more high-riskpatients appear to be responding,” stated the leadinvestigator, Azra Raza, MD, of Rush-Presbyterian-St. Luke’s Medical Center in Chicago.
9
events associated with arsenic trioxide aremanageable and reversible when patient care isprovided in accordance with TRISENOX® completeprescribing information.
Adverse events associated with arsenic trioxide,administered alone or in combination with otherchemotherapeutic agents, are listed in Table 2. Mostof the common adverse events reported in patientstreated with arsenic trioxide are of mild or moderateintensity (grade 1 or 2). A generalized rash occursin approximately 35 to 50% of patients, and topicalantihistamines or corticosteroids can be used totreat associated symptoms such as pruritus. Therash is a nonspecific drug reaction and not a truehypersensitivity or allergic drug reaction. Nauseamay be related to the infusion rate of arsenictrioxide, and antiemetics such as promethazine orprochlorperazine are effective in treating drug-relatednausea. It should be noted that severe nausea andvomiting requiring prophylactic antiemetics areuncommon. As is the case with many chemotherapeuticdrugs, adverse events decrease in incidence andseverity with continued arsenic trioxide use andrarely require interruption of therapy.
Preliminary findings from clinical trials utilizingarsenic trioxide alone, or in combination withthalidomide, have yielded encouraging data forpatients with MDS. Major and minor hematologic
Table 2. Arsenic Trioxide Safetyand Toxicity Profile
Dose-limiting Toxicities
– Fluid retention, weight gain
– Neuropathy
– Myelosuppression (neutropenia)
Common Side Effects Associated with Arsenic Trioxide
– Pain – Fever
– Cytopenia – Rash
– Nausea – Dyspnea
– Diarrhea – QT prolongation
– Edema – APL differentiation syndrome
– Fatigue
Table 3. Summary of MDS StudiesTransfusion
IndependenceStudy No. Pts. RAEB/CMML RA/RARS Total or ReductionPrincipal Investigator Treatment (Evaluable) (High-risk MDS) (Low-risk MDS) MDS of Transfusion—————————————————————————————————————————————————————————————Phase I/II MDS (US) – Trisenox 0.25 mg/kg IV 67 (62) 4*/33 (12%) 8/29 (28%) 12/62 (19%) 8/55 (15%)List et al. (2004) – 4-wk cycle (5 days/week for 2 weeks)—————————————————————————————————————————————————————————————Phase I/II MDS (EU) – Trisenox Load: 0.3 mg/kg IV, 105 (101) 18†/62 (29%) 9/39 (23%) 27/101 (27%) RBC: Vey et al. (2004) 5 days/wk 1 16/83 (19%)
– Maintenance: 0.25 mg/kg IV, Platelet:2x/wk, wks 2-16 5/38 (13%)
—————————————————————————————————————————————————————————————Phase I/II MDS (US) – Trisenox 0.25 mg/kg IV (M–F) 28 (28) 5/13 (38%) 1/6 (17%) 7/28 (25%)‡ 6/28 (21%)Raza et al. (2004) – 6-wk cycle (5 days/week for 2 weeks)
– Thalidomide 100 mg (po qd), study duration
– Vitamin C 500 mg (po qd)– Evaluable—completed at least 3 cycles
of Tx & end-of-study bone marrow—————————————————————————————————————————————————————————————*CMML=CR; †RAB=CR; ‡One responder was unclassified
REFERENCE
1. Oliva C, Kirkart B, Maxon MS, Earhart R. Safetyexperience with TRISENOX® (arsenic trioxide). In:Abstracts and Program of the 9th Congress of theEuropean Hematology Association, June 10–13, 2004,Geneva, Switzerland. Abstract #1373.
Arsenic Trioxide in MDS: An Overview of Clinical Studiesresponses as well as effects on transfusiondependence can be viewed as significantachievements in improving the health and quality of life of MDS patients (see Tables 3 and 4).
10
Single-agent and combination arsenic trioxidestudies provide a basis for potential alternativetreatments for patients with MDS. Ongoing and futureclinical trials utilizing arsenic trioxide in combinationwith 5-azacytidine or candidate therapies for MDS,
such as GM-CSF and vitamin C, have beenproposed. The results of these studies will allowevaluation of the therapeutic potential of arsenictrioxide for the treatment of MDS.
Table 4. Summary of MDS Responses
Study Response Response Type High Risk Low Risk—————————————————————————————————————————————————————————————Phase I/II MDS (US) Erythroid Response Major 2 (1 CR) 3List et al. (62 evaluable patients) (2004) Minor 1 2
Platelet Response Major 1 2Minor – –
Neutrophil Response Major 1 2Minor – 1
————————————————————————————————————————————————————————————— Phase I/II MDS (EU) Erythroid Response Major 7 (1 CR) 4Vey et al. (101 evaluable patients) (2004) Minor 2 3
Platelet Response Major 6 1Minor 1 1
Neutrophil Response Major 7 –Minor – –
————————————————————————————————————————————————————————————— Phase I/II MDS (US) Erythroid Response Major Not reported Not reportedRaza et al. (2004) Minor Not reported Not reported
Platelet Response Major Not reported Not reportedMinor Not reported Not reported
Neutrophil Response Major Not reported Not reportedMinor Not reported Not reported
————————————————————————————————————————————————————————————— International Working Group (IWG) Criteria Iinternational Prognostic Scoring System (IPSS) Risk Classification
REFERENCES
1. Erba HP. Recent progress in the treatment ofmyelodysplastic syndrome in adult patients. CurrentOpin Oncol. 2003;15:1–9.
2. List AF, Schiller GJ, Mason J, et al. Arsenic trioxide inpatients with myelodysplastic syndromes (MDS):preliminary results of a phase II clinical study. In:Abstracts and Program of the 40th Annual Meeting ofthe American Society of Clinical Oncology, June 5–8,2004, New Orleans, LA. Abstract #6512.
3. List A, Beran M, DiPersio J, et al. Opportunities forTRISENOX® (arsenic trioxide) in the treatment ofmyelodysplastic syndromes. Leukemia. 2003;17:1499–1507.
4. Oliva C, Kirkart B, Maxon MS, Earhart R. Safetyexperience with TRISENOX® (arsenic trioxide). In:Abstracts and Program of the 9th Congress of theEuropean Hematology Association, June 10–13, 2004,Geneva, Switzerland. Abstract #1373.
5. Raza A, Buonamici S, Lisak L, et al. Arsenic trioxideand thalidomide combination produces multi-lineagehematological responses in myelodysplastic syndromespatients, particularly in those with high pre-therapy EVI1expression. Leuk Res. 2004;28:791-803.
6. Vey N, Dreyfus F, Guerci A, et al. TRISENOX® (arsenictrioxide) in patients with myelodysplastic syndromes(MDS): preliminary results of a phase I/II study. In:Abstracts and Program of the 9th Congress of theEuropean Hematology Association, June 10–13, 2004,Geneva, Switzerland. Abstract #467.
11
MDSMembership InformationThe MDS Foundation would like to have you as amember. Membership is US$35 a year for physiciansand other professionals. Patients, their families, andothers interested in MDS may join at the reduced rateof $20.
Membership benefits include quarterly issues of the MDS News, a special subscription rate of $109 forLeukemia Research (a substantial discount from the current subscription rate of $1,193), and the worldwideCenters of Excellence patient referral service.
If you would like additional information, please contact us at: The MDS Foundation
36 Front StreetP.O. Box 353Crosswicks, NJ 08515
Phone: 1-800-MDS-0839 Fax: 609-298-0590Outside the US only: 609-298-1035
Blood & MarrowTransplant NewsletterBlood & Marrow Transplant Newsletter is publishedfour times annually by BMT InfoNet. To subscribe, contact:BMT InfoNet2900 Skokie Valley RoadSuite BHighland Park, IL 60035
Toll free: 888-597-7674Tel: 847-433-3313Fax: 847-433-4599E-Mail: [email protected] Web: www.bmtinfonet.org
We would like to invite you to participate in selectedstudy groups and share your experience living withMDS and the quality-of-life issues that you face.The information we develop will be used to educatehealthcare professionals about MDS patients’ needsin dealing with these diseases. The number of
groups and their location will depend upon theresponses we receive. Please join us in this mostimportant endeavor. Further developments will beposted on our website or for more informationcontact Audrey Hassan our Patient Liaison at 1-800-MDS-0839.
Patients: Your Help is Needed!
A Living EndowmentMany families are affected by living with the realityof MDS. There is an extraordinary way to contributeto the MDS Foundation and support our mission ofworking as a resource for patients, families, andhealthcare professionals.
A commitment to donate to the Foundation onoccasions of loss, birthdays and anniversaryremembrances can be made. Honor your friends orfamily members on these occasions with a donation,and The MDS Foundation will send an acknowledgmentto the recipient, recognizing the occasion.
The MDS Foundation is grateful for communitysupport. Our work as a non-profit organizationdepends on public funding.
If you would like to contribute in this way, please write to us at:
36 Front StreetP.O. Box 353Crosswicks, NJ 08515
or call us at 1-800-MDS-0839.
A Living Endowment donation has been made in honor of:
Dr. Norman Zwiebel
This donation has been submitted by:The Silverman Family, Del Ray Beach, FL
A Living Endowment donation has been made in honor of:
Paul Hedding
This donation has been submitted by:
Wendell and Chris Wagner, Gregory, MI Randy and Heidi Drake, Adrian, MISusan Mullinix, Adrian, MIBarbara Fike, Dexter, MILee and Mardelle Drake, Adrian, MIPaul Drake, Kalamazoo, MI
12
Eighth InternationalSymposium on MDS
The Eighth InternationalSymposium on MDS willbe held in Nagasaki,Japan, from May 12–15,2005. Professor MasaoTomonaga is Presidentof the symposium’sOrganizing Committee.
The Scientific Committeeincludes John M. Bennett,MD (USA), Yataro Yoshida(Honorary President),Keisuke Toyama (HonoraryChair), David T. Bowen,
H. Joachim Deeg, Theo J.M. de Witte, Pierre Fenaux,Ulrich Germing, Peter Greenberg, Henrik Hasle, EvaHellström-Lindberg, Michele M. Le Beau, Alan F. List,Ghulam J. Mufti, Charlotte Niemeyer, Stephen D.Nimer, Azra Raza, Guillermo F. Sanz, Richard Stone,Pierre J. Wijermans, and Neil Stuart Young.
Nagasaki’s Brick Hall, the venue for the symposium.From left, Professor Masoa Tomonaga, President of the 8thInternational Symposium, and Yasushi Miyazaki, MD.
A view of “beautiful Nagasaki”.
Professor Yataro Yoshida, Honorary President of the Symposium in Nagasaki.
Nagasaki City is located on the west side of Kyushuisland. Rich in culture, Nagasaki was the Windowto the World during the 17th–19th centuries (Shogunera), and provided Japan with its first contact withWestern medicine via the Dutch traders that frequentedthis all important port. Since the atomic bomb wasdetonated in 1945, Nagasaki has become a symboliccity of peace in Japan. There you will find a smalland beautiful city influenced by both European andAsian cultures.
The second announcement will be distributedwithin the next few weeks and will provide detailson the scientific program, social events, andaccommodations. You may obtain a copy by mail,phone, or fax. The Scientific Secretariat may becontacted as follows:
Symposium Secretariat8th MDS SymposiumNagasaki Brick HallPhone: (81)-95-849-7111 Fax: (81)-95-849-7113 Email: [email protected]
A call for papers will be sent out shortly. The deadlinefor submission of abstracts is January 15, 2005.
We are looking forward to welcoming you to the 8thInternational Symposium on MDS next year!
Cell Therapeutics, Inc. has provided the MDS Foundation withunrestricted educational grants to support the Foundation’s work.
13
MDS Patient RegistryThe patient registry form has been revised and apatient authorization form has been developed tomeet the new HIPAA guidelines. The PatientRegistry will help further research into the etiology,diagnosis and treatment of MDS. Currently, the MDSPatient Registry is only accepting patients throughour designated Centers of Excellence. A two pagedata sheet will be forwarded to investigators whowish to contribute patient’s names to the Registry.The Registry is located at the MDS Foundation’sStatistical Center at the University of RochesterCancer Center. The Foundation looks forward tobuilding the Patient Registry with our Centers ofExcellence. If you would like to become a Center ofExcellence, please contact The Foundation at theaddress below.
The MDS Foundation 36 Front StreetPO Box 353 Crosswicks, NJ 08515
Phone: 1-800-MDS-0839 within the USOutside the US only: 1-609-298-6746 Fax: 1-609-298-0590
MDSAbout the FoundationThe Myelodysplastic Syndromes Foundation wasestablished by an international group of physiciansand researchers to provide an ongoing exchange ofinformation relating to MDS.
Until the Foundation was set up, no formal workinggroup had been devoted to MDS. During the pastdecade we have conducted seven internationalsymposia—in Austria, England, the United States,Spain, Czech Republic, Sweden, and France. TheEighth International Symposium is being held May12–15, 2005 in Nagasaki, Japan.
A major Foundation effort is our internationalinformation network. This network provides patientswith referrals to Centers of Excellence, contactnames for available clinical trials, sharing of newresearch and treatment options between physicians,and extension of educational support to bothphysicians and patients.
In response to the needs expressed by patients,families, and physicians, we have establishedpatient advocacy groups, research funding, andphysician education.
The MDS Foundation is a publicly supportedorganization, exempt from federal income taxunder section 501(C)(3) of the IRS code.
Our WebsiteThe MDS Foundation Web page is for healthcareprofessionals, patients, and other interestedpeople. The Professional Forum and the PatientForum are integral parts of our Web site.
The Website is constantly being updated to betterserve the needs of our patients, their families, and the physicians who treat them.
We welcome your suggestions.
Please visit us at http://www.mds-foundation.org
Pfizer has provided the MDS Foundation with unrestrictededucational grants to support the Foundation’s work.
14
MDSWould you like your treatment center to become part of the referral system for MDS patients and be designated as a Center ofExcellence? To be recognized as a Center of Excellence, an institution must have the following:■ An established university (or equivalent) program■ Recognized morphologic expertise in MDS■ Available cytogenetics and/or molecular genetics■ Ongoing research, including Institutional Review ■ Board–approved clinical trials
UNITED STATESBarbara Ann Karmanos Cancer InstituteWayne State UniversityDetroit, Michigan Charles A. Schiffer, MD
The Cancer Center of Hackensack University Medical CenterHackensack, New JerseyStuart Goldberg, MD
Cedars-Sinai Medical CenterUCLA School of MedicineLos Angeles, CaliforniaH. Phillip Koeffler, MD
City of Hope National Medical CenterDuarte, CaliforniaStephen J. Forman, MD
Cleveland Clinic FoundationTaussig Cancer CenterCleveland, OhioJaroslaw Maciejewski, MD, PhD
Dana-Farber Cancer InstituteBoston, MassachusettsRichard M. Stone, MD
Duke UniversityDuke University Medical CenterDurham, North CarolinaCarlos M. deCastro, MD
Fred Hutchinson Cancer Research CenterSeattle, WashingtonJoachim Deeg, MD
Indiana UniversityIndiana University Medical CenterIndianapolis, IndianaLarry Cripe, MD
Johns Hopkins Oncology CenterJohns Hopkins InstitutionsBaltimore, MarylandSteven D. Gore, MD
Mayo ClinicPhoenix, ArizonaJames L. Slack, MDMayo ClinicJacksonville, FloridaAlvaro Moreno-Aspitia, MDMayo ClinicRochester, MinnesotaLouis Letendre, MD
MCP Hahnemann UniversityPhiladelphia, PennsylvaniaEmmanuel C. Besa, MD
Medical College of WisconsinBone Marrow Transplant ProgramMilwaukee, WisconsinDavid H. Vesole, MD, PhD, FACP
Memorial Sloan-Kettering Cancer CenterNew York, New YorkStephen D. Nimer, MD
National Heart, Lung, and Blood InstituteBethesda, MDElaine Sloand, MD
New York Medical College/Westchester Medical CenterZalmen A. Arlin Cancer CenterValhalla, NYKaren Seiter, MD
New York Presbyterian HospitalColumbia College of Physicians and Surgeons
New York, New YorkCharles Hesdorffer, MD
New York University School of MedicineNorth Shore University HospitalManhasset, New YorkSteven L. Allen, MD
Oregon Cancer Center atOregon Health & Science University
Portland, OregonPeter T. Curtin, MD
Roswell Park Cancer CenterBuffalo, New YorkMaria R. Baer, MD
Rush Cancer InstituteRush–Presbyterian– St. Luke’s Medical CenterChicago, Illinois
Seattle Cancer Care AllianceUniversity of WashingtonSeattle, WashingtonJohn A. Thompson, MD
Southwest Regional Cancer CenterAustin, TexasRichard Helmer, III, MD
Stanford UniversityStanford University Medical CenterStanford, CaliforniaPeter L. Greenberg, MD
St. Jude Children’s Research HospitalMemphis, TennesseeGregory Hale, MD
Tufts University School of MedicineNew England Medical CenterBoston, MassachusettsGeoffrey Chan, MD
University of Alabama at BirminghamComprehensive Cancer CenterBirmingham, AlabamaPeter Emanuel, MD
University of ArizonaArizona Cancer CenterTucson, ArizonaDaruka Mahadevan, MD, PhD
University of ChicagoUniversity of Chicago Medical CenterChicago, IllinoisRichard A. Larson, MD
University of NebraskaUniversity of Nebraska Medical CenterOmaha, NebraskaLori Maness, MD
University of New MexicoHealth Sciences CenterAlbuquerque, New MexicoRobert Hromas, MD
University of PennsylvaniaUniversity of Pennsylvania Cancer CenterPhiladelphia, PennsylvaniaSelina Luger, MD
University of RochesterUniversity of Rochester Cancer CenterRochester, New YorkJohn M. Bennett, MD
University of South FloridaH. Lee Moffitt Cancer Center
and Research InstituteTampa, FloridaAlan F. List, MD
University of TexasMD Anderson Cancer CenterHouston, TexasElihu H. Estey, MD
Washington University School of MedicineBarnard Cancer CenterSt. Louis, MissouriJohn F. DiPersio, MD, PhD
Weill Medical College of Cornell UniversityNew York Presbyterian HospitalNew York, New YorkEric J. Feldman, MD
The Western Pennsylvania Cancer InstitutePittsburgh, PennsylvaniaRichard K. Shadduck, MD
William Beaumont Hospital Cancer Center
Royal Oak, MIIshmael Jaiyesimi, MD
OUTSIDE THE UNITED STATESA.C. Camargo Hospital–Cancer CenterSão Paulo, BrazilLuiz Fernando Lopes, MD, PhDAcademic Hospital, Free University AmsterdamAmsterdam, The NetherlandsG.J. Ossenkoppele, MD, PhDAthens University, Evangelismos HospitalAthens, Greece Theofanis Economopoulos, MDCasa Sollievo Della Sofferenza HospitalS. Giovanni Rotondo, Italy Pelligrino Musto, MDFundeni Clinical InstituteBucharest, RomaniaRadu Gologan, MD, PhDHannover Medical SchoolMedizinische Hochschule HannoverHannover, GermanyProf. Dr. Arnold GanserHeinrich-Heine University Düsseldorf University HospitalDüsseldorf, GermanyUlrich Germing, MDHôpital Avicenne/University Paris XIIIBobigny, FrancePierre Fenaux, MDHôpital Claude Huriez, CHU LilleService des Maladies du SangLille, FranceBruno Quesnel, MDHôpital Cochin/University Paris VParis, FranceProf. Francois Dreyfus, PU-PHHôpital Saint Louis, University Paris VIIParis, FranceProf. Christine ChomienneHospital Universitario de SalamancaSalamanca, SpainProf. Jesus F. San MiguelHospital Universitario La Fe Valencia, SpainMiguel A. Sanz, MD, PhDInstitute of Hematology and Blood TransfusionPrague, Czech RepublicJaroslav Cermák, MD, PhDJagiellonian University, Collegium MedicumKrakow, PolandAleksander Skotnicki, MD, PhDJohann Wolfgang Goethe University Frankfurt Main, GermanyJohannes Atta, MDKarolinska Institute, Huddinge University HospitalStockholm, SwedenEva Hellström-Lindberg, MD, PhDKing Chulalongkorn Memorial HospitalPathumwan, Bangkok, ThailandTanin Intragumtornchai, MDKing’s College HospitalGuy’s Kings Thomas School of MedicineLondon, EnglandProf. Ghulam J. MuftiKyoto University HospitalKyoto, JapanTakashi Uchiyama, MDLudwig Maximilians UniversitätMunich, Germany Torsten Haferlach, MDNagasaki University Hospital School of MedicineAtomic Bomb Disease InstituteNagasaki City, JapanProf. Masao TomonagaOdense University HospitalThe University of Southern DenmarkOdense, DenmarkGitte Birk Kerndrup, MDPatras University HospitalPatras, GreeceNicholas C. Zoumbos, MD, PhD
Peter MacCallum Cancer InstituteUniversity of MelbourneEast Melbourne, Victoria, AustraliaJohn F. Seymour, MD
Rigshospitalet, National University HospitalCopenhagen, DenmarkLars Kjeldsen, MD, PhD
Royal Bournemouth HospitalBournemouth, United KingdomSally Killick, MD
Saitama Medical School HospitalMorohongo, Iruma, JapanAkira Matsuda, MD
St. Johannes HospitalHeinrich-Heine UniversityDuisburg, GermanyCarlo Aul, MD, PhD
Tel-Aviv Sourasky Medical CenterTel-Aviv, IsraelMoshe Mittelman, MD
Tokyo Medical CollegeTokyo, JapanKazuma Ohyashiki, MD
Universidade Federal de CearáCeará, BrazilFernando Barroso Duarte, MD
Universität HamburgHamburg, GermanyNicolaus Kröger, MD, PhD
Universitätsklinikum Carl Gustav CarusDresden, GermanyUwe Platzbecker, MD
University of Århus, The University HospitalÅrhus, DenmarkProfessor Johan Lanng Nielsen
University of Athens, Laikon HospitalAthens, GreeceNora Viniou, MD
University of Cape TownGroote Schuur HospitalCape Town, Cape South AfricaNicolas Novitzky, MD, PhD
University of Dundee Medical SchoolDundee Teaching HospitalDundee, ScotlandDavid T. Bowen, MD
University of Florence, Azienda OSP CareggiFlorence Italy
University of Freiburg Medical CenterFreiburg, GermanyMichael Lübbert, MD, PhD
University Hospital Benjamin FranklinBerlin, GermanyWolf–Karsten Hofmann, MD, PhD
University Hospital of InnsbruckInnsbruck, Austria
University of NijmegenUniversity Hospital St. RadboudNijmegen, The NetherlandsTheo J.M. deWitte, MD, PhD
University of Pavia Medical SchoolIRCCS Policlinico San Matteo, Pavia, Italy Mario Cazzola, MD
University of Tasmania, Royal Hobart HospitalHobart, Tasmania, Australia Prof. Raymond M. Lowenthal, MD, FRCP, FRACP
University of TorontoHospital for Sick ChildrenToronto, Ontario, Canada Yigal Dror, MD
University Tor VergataOspedale S. EugenioRoma, Italy Sergio Amadori, MD
University of ViennaVienna, AustriaPeter Valent, MD
■ Documentation of peer-reviewed publications in the field■ The ability and intention to register patients in the MDS
International Registry databasePlease contact the Foundation for further information and anapplication form for your center.
The following centers have qualified as MDS Centers of Excellence:
Centers of Excellence
v
15
A.
C.
B.
A. Understanding Myelodysplastic Syndromes:A Patient HandbookPeter A. Kouides, MD; John M. Bennett, MD
B. Transfusion-Dependent Iron Overloadand MDS: A Handbook for PatientsPublished by The MyelodysplasticSyndromes Foundation
Patient ReferralsMyelodysplastic syndromes can be difficult todiagnose and treat. It is important for bothpatients and their families to know that optimaltreatment is available and that quality-of-life canbe enhanced.
If you would like information about treatmentoptions, research, or quality-of-life, we would beglad to help. The Foundation offers a variety ofpatient services, including preferential referralsto the Foundation’s MDS Centers of Excellence.
Please contact us at:1-800-MDS-0839 (phone)or 609-298-0590 (fax).Outside the US please call:609-298-1035.
You can visit our website at http://www.mds-foundation.org.
MDS EducationalResources for CliniciansThe Myelodysplastic Syndromes Pathobiologyand Clinical Management(Basic and Clinical Oncology Series/27)
Edited by: John M. BennettJames P. Wilmot Cancer Center
of the University of Rochester,Rochester, New York, U.S.A.
May 2002/528 pp., illus., ISBN: 0-8247-0782-6/$165.00CRC Press. 800-272-7737When ordering, use code PAO50203
This reference provides a comprehensive overviewof the latest research detailing the etiology,epidemiology, treatment, and detection ofmyelodysplastic syndromes (MDS)—identifyingeffective therapeutic regimens, adverseenvironmental and genetic factors, and efficientmodalities of supportive care that improve patientsurvival and enhance quality of life.
A NEW CME PROGRAM AVAILABLEIN CD-ROM FORMAT
The Myelodysplastic Syndromes:Controversies in Classification andAn Optimistic Look at New Treatment Options.
You may request this program by contacting theFoundation at 800-MDS-0839 or by logging on to our website: www.mds-foundation.org.
PATIENT INFORMATION AND EDUCATIONAL MATERIALS AVAILABLEFROM THE MDS FOUNDATION
C. Patient DiaryPublished by The Myelodysplastic Syndromes Foundation
D. Your Journal:Learning AboutMyelodysplasticSyndromes (MDS)Supported by a grant from Celgene Corporation.
All of these materials are available free of chargefrom the Foundation.
SuperGen has provided theMDS Foundation with unrestricted educational
grants to support the Foundation’s work.
16
International Clinical TrialsThe following trials are current as of the date of thisnewsletter. We will update the list in The MDS Newseach quarter. If you are a treating physician whowould benefit from any such study, you may wantto contact the appropriate institution. If you are anMDS patient, you may wish to discuss a trial withyour primary treating physician to see if you qualifyas a candidate.
Clinical trials study new interventions (drugs orprocedures) to evaluate their safety and effective-ness in humans. Trials follow a careful set of steps,allowing for the systematic gathering of informationto answer questions and confirm hypotheses thatwere formed earlier, in either laboratory experimentsor preliminary trials.
A clinical trial falls into one of four phases:
Phase I. This is the first time a drug is used inhumans. The trial is designed to determine dosage,route of administration (oral, intravenous, or byinjection), and schedule of administration (how manytimes a day or week). In this phase researchers alsobegin to determine the drug’s safety. The phase I trialis normally conducted in healthy adults and enrollsonly a small number of people.
Phase II. Patients with the disease receive the drugat dose levels determined in the earlier phase. Thephase II trial begins to determine the effectivenessof the drug and provides more information aboutits safety.
Phase III. The drug is tested alone or against anapproved standard drug. The typical phase III trialenrolls a large number of patients. If it is a comparisontrial, patients may be randomly assigned to receiveeither the new drug or the standard intervention.
Phase IV. In phase IV the drug, already approvedby the FDA and available to the public, undergoescontinued evaluation. The phase IV designation is rare.
Some trials—screening studies evaluatingsupportive care or prevention —are not conducted inphases. In these trials a group following a certaindisease combating strategy, such as a detectionmethod, is compared to a control group.
U.S. TrialsNATIONAL CANCER INSTITUTE TRIALS*
As we go to press the National Cancer Institute (NCI) haslisted more than 100 clinical trials that focus onMyelodysplastic syndromes. Full study information onthese trials is available at www.nci.nih.gov. This infor-mation includes basic study information, study leadorganizations, study sites, and contact information. Toaccess the information:
■ Log on to www.nci.nih.gov■ Click on “Finding Clinical Trials”■ on the next screen look for “Ways to Find Clinical
Trials” and■ Click on “Search for Clinical Trials”■ Click on “Type of Cancer” and type in
‘myelodysplastic syndromes’■ Hit search
This search will provide you with all the trials currentlyunderway in MDS. You may also sort by trials that onlyfocus on treatment or trials that only focus on supportivecare. You can also contact 1-800-4-CANCER for moreinformation.
ADVANCED CANCERS:A NEW TRANSPLANT METHOD
Researchers at the National Institutes of Health(NIH/DHHS) are investigating a new method of improvingtransplant results in individuals with advanced cancers. Ifyou or someone you know are between the ages of 10 to50 years old and have one of the following cancers:Myelodysplastic Syndrome, Leukemia, or MyeloproliferativeDisorder, you may be able to participate in this clinical trial.To find out if you qualify, please call 1-800-411-1222 or visitwww.cc.nih.gov.
Pharmion. AZA PH GL 2003 CL 001. A Survival Study inPatients with High Risk Myelodysplastic SyndromesComparing Azacitidine versus Conventional Care. Thepurpose of this study is to determine whether patients withhigh-risk myelodysplastic syndromes (MDS) treated withazacitidine have improved survival compared toconventional care treatments. The study will also assessthe effect of treatments on response, duration of response,and transformation to acute myeloid leukemia (AML).
Telik, Inc. Phase I-IIa trial to evaluate the safety andefficacy of TLK199 in patients with myelodysplasticsyndrome (MDS). Eligible patients must have a diagnosisof MDS, be at least 18 years old and ineligible or refusingbone marrow transplant.
Novartis. Phase I, open-label, dose escalating study toevaluate the safety, biologic activity and pharmacokineticprofile of LAQ824 in patients with relapsed or refractoryAML, CLL, or CML in blast crisis, or advanced MDS. The
17
primary objective of this study is to determine theMaximum Tolerated Dose (MTD) and Dose Limiting Toxicity(DLT) of LAQ824 as a single agent when administered byintravenous infusion as outlined in the protocol.
An Open-label Phase II Trial of PKC412 Monotherapy inPatients with Acute Myeloid Leukemia and Patients withMyelodysplastic Syndrome PKC4122104. Patients whoagree to participate in this trial will be screened for theFLT3 mutation. If positive, they will have a physical exam,blood test, EKG, chest x-ray, bone marrow aspirate and apregnancy test.
For more information, please go to www.clinicaltrials.gov.
Other U.S. TrialsBarbara Ann Karmanos Cancer Institute, Detroit, MI.D-696. Allogenic and syngenieic marrow transplantation inpatients with acute non-lymphocytic leukemia. Contact:Jared Klein, MD. Phone: 313-963-2533.
Barbara Ann Karmanos Cancer Institute, Detroit, MI.POG A2971: Treatment Of Children with Down Syndromeand Acute Myeloid Leukemia, Myelodysplastic Syndrome,or Transient Myeloproliferative Disorder. Contact: JeffreyTaub, MD. Phone: 313-963-2533.
Cancer and Blood Institute of the Desert, Rancho Mirage,CA. Phase I/II study of arsenic trioxide in combination withcytosine arabinoside in patients with MDS. Contact: R.Lemon. Phone: 760-568-4461. Cancer Institute MedicalGroup, Los Angeles, CA. Phase I/IIa Study of TLK199 HClLiposomes for injection in Myelodysplastic Syndromes.Contact: Lawrence D. Piro, MD. Phone: 310-231-2182.
Case Western Reserve University, Cleveland, OH. AZAPH GL 2003 CL 001. Multicenter randomized open-labelparallel group phase III trial of subcutaneous azacitidineplus best supportive care versus conventional careregimens plus best supportive care for the treatment ofMyelodysplastic Syndromes (MDS). Contact: Donna Kane,RN. Phone: 216-844-8609.
Case Western Reserve University, Cleveland, OH.CWRU-5Y97. Phase II trial using umbilical cord blood toevaluate the efficacy of transplantation to treat aplasticanemia and myelodysplastic syndromes patients. Eligiblepatients must have disease not responsive to medicaltherapy. Contact: Mary J. Laughlin. Phone: 216-844-8609.
Cedars-Sinai Medical Center, Los Angeles, CA. 02287.Phase II Trial of Paricalcitol in Myelodysplastic Syndromesto determine if an oral, relatively non-toxic, novel vitaminD3 compound, paricalcitol, (Zemplar) can improve red,white and platelet counts as well as decrease the risk ofdevelopment of leukemia, without causing undue toxicityin patients with myelodysplastic syndromes (MDS).Patients will receive oral administration of paricalcitol inincreasing doses. Contact: H. Phillip Koeffler, MD. Phone:310-423-4609.
Children’s Hospital of New York Presbyterian, New York,NY. 01-504. Phase II trial using fludarabine, busulfan, andanti-thymocyte globulin (ATG) to evaluate the efficacy ofreduced intensity allogeneic stem cell transplantation totreat MDS. Eligible patients must have 1) MDS and <5%bone marrow myeloblasts at diagnosis; 2) minimum of>10% CD33 positivity; 3) adequate organ function (renal,hepatic, cardiac and pulmonary); 4) age <65 years; 5)matched family donor (5/6 or 6/6), unrelated donor (5/6 or6/6), or cord blood donor (3/6, 4/6, 5/6, 6/6). Contact:Mitchel S. Cairo, MD. Phone: 212-305-8316.
Cleveland Clinic Foundation, Cleveland, OH. IRB5777.Phase II, multicenter, open-label study of the safety andefficacy of high-dose pulse administration DN-101(calcitrol) in patients with myelodysplastic syndrome.Contact: Liz Kuczkowski. Phone: 216-445-3795.
Cleveland Clinic Foundation, Cleveland, OH. Phase II trialof combination therapy with arsenic trioxide (Trisenox) andgemtuzumab ozogamicin (Mylotarg) for the treatment ofadult patients with advanced myelodysplastic syndromes.Contact: Liz Kuczkowski. Phone: 216-445-3795.
Comprehensive Cancer Institute. Huntsville, AL. Phase IIstudy of arsenic trioxide (Trisenox) in patients with MDS.Contact: J.M. Waples, MD. Phone: 256-551-6546.
Dana-Farber Cancer Institute, Boston, MA. Phase I Studyof Vaccination with Lethally Irradicated, Autologous AcuteMyeloblastic Leukemia Cells Engineered by AdeonviralMediated Gene Transfer to Secrete Human Granulocyte-Macrophage Colony Stimulating Factor in Patients withAdvanced Myelodysplasia or acute MyelogenousLeukemia. This is a study to determine the feasibility ofpreparing lethally irradiated autologous myeloblasticleukemia cells engineered by adenoviral mediated genetransfer to secrete GM-CSF in patients with myelodysplasiaor acute myelogenous leukemia. The study will alsoinvestigate the safety and biologic activity of vaccinationwith lethally irradiated, autologous myeloblastic leukemiacells engineered by adenoviral mediated gene transfer tosecrete GM-CSF in patients with advanced myelodysplasiaor acute myelogenous leukemia. Contact: Ilene Galinsky.Phone: 617-632-3902.
Duke University Medical Center, Durham, NC. Phase IItrial to assess the value of non-myeloablative allogeneictherapy (mini bone marrow transplant) for patients withaplastic anemia or myelodysplastic syndromes. Patientsmust have severe disease to be eligible and may haveeither a matched sibling, mismatched family member, orlarge cord blood unit found for use on our trial. Contact:David A. Rizzieri, MD at [email protected].
Fallon Clinic. Worcester, MA. PR01-09-010. Phase II studyon the effectiveness of low dose Thalidomide combined withErythropoietin in the treatment of anemia in patients with lowand intermediate risk-1 myelodysplastic syndromes.Contact: Laszlo Leb, MD. Phone: 508-368-3168.
18
Fox Chase, BMT Program, Philadelphia, PA. 3297.Phase II trials using fludarabine-based regimen toevaluate the efficacy of mini-allogeneic blood stem celltransplantation to treat myelodysplastic syndromes.Eligible patients must have HLA identical donoravailable, be under age 70 and platelet or red celltransfusion dependent. Patients with matched relateddonors will be considered up to age 70 with KarnofskyPerformance Scale >80%. Patients with matchedunrelated donor will be considered to age 65 only.Contact: Marge Bellergeau, RN. Phone: 215-214-3122.
Fred Hutchinson Cancer Research Center, Seattle, WA.FHCRC #1297. Radiolabeled BC8 (anti-CD-45) AntibodyCombined with Cyclophosphamide and Total BodyIrradiation Followed by HLA-Matched Related or UnrelatedStem Cell Transplantation as Treatment for AdvancedAcute Myeloid Leukemia and Myelodysplastic Syndrome.Phase II trial to determine the efficacy (as measured bysurvival and disease-free survival) and toxicity of aregimen of cyclophosphamide, TBI, plus the maximumtolerated dose of I labeled BC8 (anti-CD45) antibody inpatients with AML beyond first remission receiving HLAmatched related hematopoietic stem cell transplants.Contact: J. Pagel, MD. Phone: 206-288-1024.
Fred Hutchinson Cancer Research Center, Seattle, WA.FHCRC #1432. Phase I trial to determine the maximumtolerated dose of radiation delivered via BC8 antibodywhen combined with the non-myeloablative regimen offludarabine, TBI+CSP/MMF in elderly patients (>50 and<70 years) with advanced AML or high risk MDS. Contact:J. Pagel, MD. Phone: 206-288-1024.
Fred Hutchinson Cancer Research Center, Seattle, WA.FHCRC #1591. Phase I trial to determine whether stableallogeneic engraftment from related and unrelated HLA-mismatched stem cell donors can be safely establishedusing a non-myeloablative conditioning regimen plusescalating doses of the anti-CD52mAb Campath® inpatients with hematologic malignancies. Contact: B.Sandmaier, MD. Phone: 206-288-1024.
Fred Hutchinson Cancer Research Center, Seattle, WA.FHCRC #1732. Phase II trial to evaluate the efficacy ofnon-myeloablative allogeneic HCT from related andunrelated donors for the treatment of patients with MDSand MPD, who are not candidates for conventionalallogeneic HCTG due to advanced age or seriouscomorbid conditions. Contact: B. Sandmaier, MD. Phone:206-288-1024.
Fred Hutchinson Cancer Research Center, Seattle, WA.FHCRC #1813. Phase III trial to compare the non-relapsemortality at 1-year after conditioning with TBI alone vs.fludarabine/TBI in heavily pretreated patients withhematologic malignancies at low/moderate risk for graftrejection who have HLA-matched related donors. Contact:B. Sandmaier, MD. Phone: 206-288-1024.
Fred Hutchinson Cancer Research Center, Seattle, WA.FHCRC #1536. Transplantation of peripheral blood stemcells from related or unrelated volunteer donors in patientswith “less advanced” MDS. Conditioning therapy includesbusulfan (targeted to a pre-determined plasma level) andcytoxan (targeted BUCY); patients up to 65 years of age.Contact: H.J. Deeg, MD. Phone: 206-288-1024.
Fred Hutchinson Cancer Research Center, Seattle, WA.FHCRC #1596. Transplantation from related donors forhigh-risk patients with MDS. Conditioning includes a “non-myeloblative” regimen of fludarabine and 200 cGy of totalbody irradiation. Patients are evaluated individually foreligibility. Contact: David Maloney, MD, PhD. Phone: 206-288-1024.
Fred Hutchinson Cancer Research Center, Seattle, WA.FHCRC #1478. Non-transplant therapy for “less advanced”MDS with ATG plus Enbrel. No age restrictions. Contact:H.J. Deeg, MD. Phone: 206-667-4324.
Fred Hutchinson Cancer Research Center, Seattle, WA.FHCRC #117. Transplantation of patients with aplasticanemia from related donors following conditioning withantithymocyte globulin (ATG) and cytoxan (CY). Patientsup to 55 years of age. Contact: R. Storb, MD. Phone: 206-288-1024.
Fred Hutchinson Cancer Research Center, Seattle, WA.FHCRC #800. Transplantation from unrelated donors forpatients with aplastic anemia who have failed immuno-suppressive therapy. Conditioning involves ATG, CY and200 cGy of total body irradiation. Patients up to 55 yearsof age. Contact: H.J. Deeg, MD. Phone: 206-288-1024.
Fred Hutchinson Cancer Research Center, Seattle, WA.FHCRC #1641. Transplantation from unrelated donors forhigh-risk patients with MDS. Conditioning will be with a“non-myeloablative” approach using 200 cGy of TB1 andfludarabine. No age restriction (other exclusion criteriaexist). Contact: M. Maris, MD. Phone: 206-288-1024.
Fred Hutchinson Cancer Research Center, Seattle, WA.FHCRC #1723. Transplantation from related or unreleaseddonors for patients with advanced MDS or myeloproliferativedisorders. Conditioning includes busulfan (targeted to apredetermined plasma level) and Cytoxan (targetedBUCY) with the addition of thymoglobulin; patients up to65 years of age. Contact: H.J. Deeg, MD. Phone: 206-288-1024.
Fred Hutchinson Cancer Research Center, Seattle,WA. FHCRC #1781. Non-transplant therapy for “lessadvanced” transfusion-dependent MDS with DN-101(Calcitriol). No age restrictions. Contact: H.J. Deeg, MD.Phone: 206-288-1024.
Froedtert Memorial Lutheran Hospital, Milwaukee, WI.AZA PH GL 2003 CL 001. Multicenter randomized open-label parallel group phase IIl trial of subcutaneousazacitidine plus best supportive care versus conventional
19
care regimens plus best supportive care for the treatmentof Myelodysplastic Syndromes (MDS). Contact: DavidVesole, MD. Phone: 414-805-4629.
Georgetown University, Washington, DC. Clinical andbiologic effects of arsenic trioxide in MDS. Contact: B.Mavromatis, MD. Phone: 202-784-0124.
H. Lee Moffitt Cancer Center, Tampa, FL. MCC# 13935.Phase I/II Trial of Subcutaneous Decitabine (5-Aza-2´-deoxycytidine) Optimizing Genomic Methylation inPatients with Myelodysplastic Syndrome (MDS). Inclusioncriteria: Histologically confirmed diagnosis of MDS ornonproliferative chronic myelomonocytic leukemia (CMML)according to FAB criteria, with IPSS category ofIntermediate-2 or High. If cytogenetics are not available,patients with >10% and <30% marrow blasts are eligible.Soon to Open. Contact: Pamela Humble, RN. Phone: 813-632-8391.
H. Lee Moffitt Cancer Center, Tampa, FL. MCC# 13937.A Pharmacokinetic and Pharmacodynamic Study of OralCC-5013 (LENALIDOMIDE; REVLIMID) In Subjects withLow- or Intermediate-1-Risk Myelodysplastic Syndromes.Inclusion criteria: Documented diagnosis of MDS thatmeets International. Prognostic Scoring System (IPSS)criteria for Low- to Intermediate-1-risk disease. Red bloodcell (RBC) transfusion-dependent anemia defined ashaving received >4 transfusions of RBCs within 56 days ofrandomization of symptomatic anemia (Hgb <9.0 g/dl).Soon to Open. Contact: Pamela Humble, RN. Phone: 813-632-8391.
H. Lee Moffitt Cancer Center, Tampa, FL. MCC# 13727. APhase lA/ll, two-arm, multicenter, dose-escalation study ofLBH589 administered intravenously on two dose schedulesin adult patients with advanced hematologic malignancies.Inclusion criteria: Patients with a cytopathologicallyconfirmed diagnosis of AML. MDS, (RAEB, RAEBT), ALL,CLL, CML, multiple myeloma, NHL including CTCL who areeither relapsed after or refractory to standard therapy, andare considered inappropriate candidates for standardtherapy. Patients with a cytopathologically confirmeddiagnosis of AML. MDS, (RAEB, RAEBT) who are previouslyuntreated but due to age, poor prognosis, or concurrentmedical conditions are considered inappropriatecandidates for standard induction therapy, or those whorefuse standard induction therapy. Contact: PamelaHumble, RN. Phone: 813-632-8391.
Indiana University Medical Center, Indianapolis, IN.AZA PH GL 2003 CL 001. Multicenter randomized open-label parallel group phase IIl trial of subcutaneousazacitidine plus best supportive care versus conventionalcare regimens plus best supportive care for the treatmentof Myelodysplastic Syndromes (MDS). Contact: LarryCripe, MD. Phone: 317-274-0901.
Johns Hopkins Oncology Center, Baltimore, MD. J0136.Vaccination in peripheral stem cell transplant setting for
acute myelogenous leukemia: The use of autologous tumorcells with an allogeneic GM-CSF producing bystander cellline. Contact: Julie Yerian. Phone: 410-614-1766.
Johns Hopkins Oncology Center, Baltimore, MD. J0255.Phase II study of the farnesyl transferase inhibitorZarnestra in previously untreated poor-risk acute myeloidleukemia and myelodysplastic syndromes. Contact: JackieGreer. Phone: 410-614-1329.
Johns Hopkins Oncology Center, Baltimore, MD. J0051.Dose finding study of bryostatin-1 and GM-CSF forresistant myeloid malignancies. Contact: Julie Yerian.Phone: 410-614-1766.
Johns Hopkins Oncology Center, Baltimore, MD. J9950.Phase I dose de-escalation to minimal effective pharma-cologic dose trial of sodium phenylbutyrate in combinationwith 5-azacytidine in patients with myelodysplasticsyndromes. Contact: Tianna Dauses. Phone: 410-502-7110.
Johns Hopkins Oncology Center, Baltimore, MD. J9879.Phase I, dose-finding trial of sodium phenylbutyrate incombination with all trans-retinoic acid (ATRA) in patientswith myelodysplastic syndromes and acute myeloidleukemia. Contact: Karen Friel. Phone: 410-502-7114.
Johns Hopkins Oncology Center, Baltimore, MD. J0253.Phase I clinical-laboratory study of the histone deacetylase(HDA) Inhibitor MS-275 in adults with refractory andrelapsed hematologic malignancies. Contact: JackieGreer. Phone: 410-614-1329.
Johns Hopkins Oncology Center, Baltimore, MD. J0252.Phase II study of the farnesyl transferase inhibitorZarnestra in complete remission following induction and/orconsolidation chemotherapy in adults with poor-risk acutemyelogenous leukemia (AML) and high-risk myelodysplasias.Contact: Jackie Greer. Phone: 410-614-1329.
Johns Hopkins Oncology Center, Baltimore, MD. J9852.Granulocyte macrophage-colony stimulating factor (GM-CSF) after T-lymphocyte-depleted allogeneic BMT formyelodysplastic syndromes. Contact: Tianna Dauses.Phone: 410-502-7110.
Los Angeles Hematology and Oncology Assoc., LosAngeles, CA. Phase I/II study of arsenic trioxide incombination with cytosine arabinoside in patients withMDS. Contact: C. Gota, MD. Phone: 818-409-0105.
MD Anderson Cancer Center, Houston, TX. Phase I/IIaStudy of TLK199 HCl Liposomes for injection inMyelodysplastic Syndromes. Contact: Stefan Faderl, MD.Phone: 713-563-1688.
MD Anderson Cancer Center, Houston, TX. Open-Label,Phase II Study to Evaluate The Efficiency and Safety of theFarnesyl-transferase Inhibitor Zarnestra (R115777) inSubjects with High-Risk Myelodysplastic Syndrome(MDS). Contact: Razelle Kurzrock, MD.
MD Anderson Cancer Center, Houston, TX. ID02-266.Therapy of inversion (16) and T (8:21) AML/MDS withfludarabine and Ara-C. Contact Elihu H. Estey, MD. Phone:713-792-7544.
MD Anderson Cancer Center, Houston, TX. Phase I/IIStudy of PR1 (NSC698102) Human Leukemia PeptideVaccine with Incomplete Freund’s Adjuvant (NSC 675756).Contact: Jeffrey Molldrem, MD. Phone: 713-745-4820.
MD Anderson Cancer Center, Houston, TX. Phase IIOpen-Label Study of the Intravenous Administration ofHomoharringtonine (CGX-635) in the Treatment ofMyelodysplastic Syndrome (MDS). Contact: Jorge Cortes,MD. Phone: 713-794-5783.
MD Anderson Cancer Center, Houston, TX. Phase IIStudy Of Arsenic Trioxide In The Treatment Of Myelodys-plastic Syndromes. Contact: Miloslav Beran, MD. Phone:713-792-2248.
MD Anderson Cancer Center, Houston, TX. Phase ll,Multicenter, Open-Label Study of the Safety and Efficacy ofHigh-Dose Pulse Administration DN-101 (Calcitriol) inPatients with Myelodysplastic Syndrome. Contact:Guillermo Garcia-Manero, MD. Phone: 713-745-3428.
MD Anderson Cancer Center, Houston,TX. Randomized,Open-Label, Phase III Trial Of Decitabine (5-AZA-2’Deoxycytidine) Versus Supportive Care In Adults WithAdvanced-Stage Myelodysplastic Syndrome. Contact:Jean-Pierre Issa, MD. Phone: 713-745-2260.
MD Anderson Cancer Center, Houston, TX. Safety AndEfficacy Trial Of Bevacizumab: Anti-VEGF HumanizedMonoclonal Antibody (NSD 704865) Therapy ForMyelodys-plastic Syndrome (MDS). Contact: Jorge Cortes,MD. Phone: 713-794-5783.
MD Anderson Cancer Center, Houston, TX. Phase IIStudy Of Neumega (Oprelvekin)(Interleukin-11) In Patientswith Myelodysplastic Syndrome. Contact: RazelleKurzrock, MD. Phone: 713-794-1226.
MD Anderson Cancer Center, Houston, TX. MulticenterPhase I/II Study Of Continuous Oral Administration Of SCH66336 In Patients With Advanced MyelodysplasticSyndrome, Acute Myelogenous Leukemia, ChronicMyelogenous Leukemia In Blast Crisis, AcuteLymphoblastic Leukemia. Contact: Jorge Cortes MD.Phone: 713-794-5783.
MD Anderson Cancer Center, Houston, TX. Phase IIStudy of Intravenous Homoharringtonine in ChronicMyelogenous Leukemia (CML). Contact: Jorge Cortes,MD. Phone: 713-794-5783.
MD Anderson Cancer Center, Houston, TX. Therapy ofHypereosinophilic Syndrome, Polycythemia Vera, AtypicalCML or CMML with PDGF-R Fusion Genes, orMastocytosis with Gleevec (STI571). Contact: JorgeCortes, MD. Phone: 713-794-5783.
MD Anderson Cancer Center, Houston, TX. DCTERChemotherapy In Patients Ages 1 Through 49 WithUntreated AML or High-Risk Myelodysplasia. Contact:Elihu Estey, MD. Phone: 713-792-7544.
MD Anderson Cancer Center, Houston, TX. Phase IIstudy of clofarabine in combination with cytarabine(Ara-C) in pts ≥50 yrs with newly diagnosed andpreviously untreated acute myeloid leukemia (AML) andhigh-risk myelodysplastic syndrome (MDS) (≥10% bonemarrow blasts). Contact: Stefan Faderl, MD. Phone:713-745-4613.
MD Anderson Cancer Center, Houston, TX. DM02-203.Phase la, Open-Label, 3-Arm, Dose Escalation Study ofPTK787/ZK 222584. Contact: Francis Giles, MD. Phone:713-792-8217.
MD Anderson Cancer Center, Houston, TX. ID03-0044.Phase I Clinical Trial of Oral Suberoylanilide HydroxamicAcid (SAHA) in Patients with Advanced Leukemias.Contact: Guillermo Garcia-Manero, MD. Phone: 713-745-3428.
MD Anderson Cancer Center, Houston, TX. DM01-646.Phase I Study of ABT-751 in Patients With RefractoryHematologic Malignancies. Contact: Francis Giles, MD.Phone: 713-792-8217.
MD Anderson Cancer Center, Houston, TX. ID99-059.Phase II trial using ATG and Fludarabine or Cyclosporineto evaluate the efficacy of immunosuppression to treataplastic anemia and myelodysplastic syndromespatients. Eligible patients must have RA or RARS and lowblood counts. Contact: Jeffrey Molldrem, MD. Phone:713-745-4820.
MD Anderson Cancer Center, Houston, TX. ID99-059.Phase II trial using ATG/CSA; ATG/Fludarabine. Eligiblepatients must have MDS of subtype RA, blasts <5% inbone marrow that require >unit of PRBC/month for >2months, platelet count <50,000/m3, or neutrophil count<500/m3, IPSS score >2. Contact: Jeffery Molldrem, MD.Phone: 713-745-4820.
Memorial Sloan-Kettering Cancer Center, New York, NY.99-057. Phase I study of salicylate for adult patients withadvanced myelodysplastic disorders, acute myelogenousleukemia or chronic lymphocytic leukemia. Contact:Virginia Klimek, MD. Phone: 212-639-6519.
Memorial Sloan-Kettering Cancer Center, New York, NY.00-116. Pilot study of FR901228 or Depsipeptide(NSC#630176) for adult patients with advancedhematologic disorders. Contact: Virginia Klimek, MD.Phone: 212-639-6519.
Memorial Sloan-Kettering Cancer Center, New York, NY.02-063. Tolerability and PK/PD of multiple oral doses ofCT53518 in patients with acute myelogenous leukemia.Contact: Mark Heaney, MD, PhD. Phone: 212-639-2275.
20
21
Mount Sinai Medical Center, New York, NY. Phase I-IIPilot Study of Divalproex Sodium and All-Trans-RetinoicAcid (ATRA) in Relapsed or Refractory Acute MyeloidLeukemia (except M3, FAB Classification). Contact: LewisSilverman, MD. Phone: 212-241-5520.
Mount Sinai Medical Center, New York, NY. AZA PH GL2003 CL 001. Multicenter randomized open-label parallelgroup phase III trial of subcutaneous azacitidine plus bestsupportive care versus conventional care regimens plusbest supportive care for the treatment of MyelodysplasticSyndromes (MDS). Contact: Lewis Silverman, MD. Phone:212-241-5520.
National Heart, Lung, and Blood Institute, Bethesda,MD. 04-H-0026. Randomized Trial of Daclizumab versusATG for Myelodysplastic Syndrome. Clinical trialcomparing the effectiveness of treatment with either a newimmuno-suppressive drug (Daclizumab) or antithymocyteglobulin (ATG) for patients with myelodysplastic syndrome.The study may help increase blood counts, reduce anemiasymptoms, and/or reduce dependence on immuno-suppressive medications and transfusions. If you aredetermined to be eligible to participate and you agree tojoin, it will be determined by chance whether you receiveeither daclizumab or ATG. If the treatment you areassigned does not work, you may subsequently receivethe other treatment. Contact: Laura Wisch. Phone: 301-402-0797.
National Heart, Lung, and Blood Institute, Bethesda,MD. 01-H-0162. Stem Cell Transplantation for OlderPatients with Myelodysplastic Syndrome. If you are 55 to75 years of age and have been diagnosed with MDS, youmay be eligible for a transplant procedure designed todecrease a major transplant complication, graft-versus-host disease (GVHD). Under evaluation is a novel methodof treating your donor’s cells prior to transplant. You musthave an HLA-matched brother or sister to participate. Wewill do the blood testing free of charge to see if your siblingis a match upon request. Contact: Laura Wisch. Phone:301-402-0797.
National Heart, Lung, and Blood Institute, Bethesda,MD. 04-H-0112. Stem Cell Transplantation and T-Cell AddBack to Treat Myelodysplastic Syndromes. Clinical trialdesigned to decrease graft versus host disease, promoteengraftment, and improve immune system recoveryfollowing a bone marrow stem cell transplant. You musthave an HLA matched brother or sister donor to participatein this trial. Contact: Laura Wisch. Phone: 301- 402-0797.
National Heart, Lung, and Blood Institute, Bethesda, MD.03-H-0209. Stem Cell Transplant for MDS from a partiallyHLA-matched family member. Many patients are notconsidered for a stem cell transplant because an HLA-matched sibling or unrelated donor is unavailable. Forsuch patients, the only curative option is a transplant from apartially HLA-matched family member. If you are 10–50 years
of age and have been diagnosed with advancedmyelodysplastic syndrome, you may be eligible for a clinicaltrial of a transplant procedure that evaluates usingperipheral blood stem cells from an HLA-mismatchedfamily donor. Eligible patients are not asked to pay for theirmedical treatment and hospital costs. Contact: LauraWisch. Phone: 301-402-0797.
New York Presbyterian Hospital, New York, NY. Phase I/IItrial of Trisenox in combination with low dose Ara-C for thetreatment of high-risk MDS and poor prognosis AML inpatients >60 years. Contact: Gail Roboz, MD. Phone: 212-746-3126.
Oregon Health & Science University, Portland, OR. AZAPH GL 2003 CL 001. Multicenter randomized open-labelparallel group phase IIl trial of subcutaneous azacitidineplus best supportive care versus conventional careregimens plus best supportive care for the treatment ofMyelodysplastic Syndromes (MDS). Contact: Peter Curtin,MD. Phone: 503-494-5064.
Oregon Health & Science University, Portland, OR.7002. Tolerability and PK/PD of Multiple Oral Doses ofCT53518 in Patients with Acute Myelogenous Leukemia.Contact: Peter Curtin, MD. Phone: 503-494-5064.
Oregon Health & Science University, Portland, OR.7597. Phase II, Multicenter, Open Label Study of the Safetyand Efficacy of High-dose Pulse Administration DN-101(Calcitriol) in Patients with Myelodysplastic Syndrome.Contact: Peter Curtin, MD. Phone: 503-494-5064.
Oregon Health & Science University, Portland, OR.7377. Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial Assessing the Safety and Efficacy ofThalidomide (Thalomid®) For the Treatment of anemia inRed Blood Cell Transfusion-Dependent Patients withMyelodysplastic Syndromes. Contact: Peter Curtin, MD.Phone: 503-494-5064.
Oregon Health & Science University, Portland, OR.7039. Randomized Controlled Trial of Posaconazole(SCH56592) vs. Standard Azole Therapy for the Preventionof Invasive Fungal Infections Among High-Risk NeutropenicPatients. Contact: Peter Curtin, MD. Phone: 503-494-5064.
Oregon Health & Science University, Portland, OR.4252. Transplantation of Unrelated Donor Marrow orPlacental Blood Hematopoietic Stem Cells for theTreatment of Hematological Malignancies. Contact: PeterCurtin, MD. Phone: 503-494-5064.
Oregon Health & Science University, Portland, OR.6756. Low-Dose TBI and Fludarabine Followed byNonmyeloablative Unrelated Donor Peripheral Blood StemCell Transplantation Using Enhanced PostgraftingImmuno-suppression for Patients with HematologicMalignancies and Renal Cell Carcinoma –A Multi-CenterTrial. Contact: Peter Curtin, MD. Phone: 503-494-5064.
22
Oregon Health & Science University, Portland, OR. 6684.Nonmyeloablative PBSC Allografting from HLA MatchedRelated Donors Using Fludarabine and Low Dose TBI withDisease-Risk Based Immunosuppression. FHCRC Protocol#1596.00. Contact: Peter Curtin, MD. Phone: 503-494-5064.
Oregon Health & Science University, Portland, OR. 6370.Low Dose Total Body Irradiation and Fludarabine Followedby HLA Matched Allogeneic Stem Cell Transplantation forHematologic Malignancies–A Multi-Center Study. Contact:Peter Curtin, MD. Phone: 503-494-5064.
Oregon Health & Science University, Portland, OR. 6615.Non-Myeloablative Allogeneic Hematopoietic Cell Trans-plantation for the Treatment of Myelodysplastic Syndromesand Myeloproliferative Disorders (Except CML). Contact:Peter Curtin, MD. Phone: 503-494-5064.
Roswell Park Cancer Institute, Buffalo, NY. PTK787. PhaseII study of an oral VEGF agent in myelodysplasticsyndromes. Contact: Maria Baer, MD. Phone: 716-845-8840.
Roswell Park Cancer Institute, Buffalo, NY. RPC-02-03.Treatment of anemia in patients with low-and intermediate-risk MDS with darbepoetin alfa. Multicenter, phase II trialalso open at the University of Alabama (Birmingham),Loyola University Medical Center (Chicago), andRochester General Hospital (Rochester, NY). Contact:Maria Baer, MD. Phone: 716-845-8840.
Rush-Presbyterian-St. Luke’s Medical Center, Chicago,IL. MDS 99-14. Pilot study of Thalidomide (Thalidomid)combined with Pentoxyfilline, Ciprofloxacin andDexamethasone (PCD) in patients with myelodysplasticsyndromes. This is a phase II trial using anticytokine andantiangiogenic therapy to evaluate the efficacy ofThalidomide (Thalomid) to treat MDS. Eligible patients musthave MDS (RA, RARS or RAEB). Addendum: Reduced doseof Pentoxyfilline (400 mg po TID), No Cipro, No Decadron.Contact: Laurie A. Lisak, MMS. Phone: 312-563-2535.
Rush-Presbyterian-St. Luke’s Medical Center, Chicago,IL. MDS 801-001. Multicenter, open-label, dose-escalationstudy to determine the safety and preliminary efficacy ofCC-1088 in treatment of myelodysplastic syndromes.Eligible patients must have RA or RARS. Contact: Laurie A.Lisak, MMS. Phone: 312-563-2535.
Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL.MDS 2000-04. Phase IIB study using Thymoglobulin intransfusion dependent patients with myelodysplasticsyndrome. Open to FAB types RA, RARS, RAEB. Contact:Laurie A. Lisak, MMS. Phone: 312-563-2535.
Rush-Presbyterian-St. Luke’s Medical Center, Chicago,IL. MDS 2000-11. Pilot study to test the efficacy ofinfliximab (Remicade) in patients with low-risk myelodysplasticsyndromes. Eligible patients must be transfusiondependent or hemoglobin <9 grams, and an IPSS score<1.5, and cannot have a history of clinically significant
cardiac disease or CHF. Contact: Laurie A. Lisak, MMS.Phone: 312-563-2535.
Rush-Presbyterian-St. Luke’s Medical Center, Chicago,IL. MDS 2001-12. Pilot study to determine the clinicaleffects of the proteasome inhibitor PS-341 in patients withmyelodysplastic syndromes. All FAB types are eligible.Contact: Laurie A. Lisak, MMS. Phone: 312-563-2535.
Rush-Presbyterian-St. Luke’s Medical Center, Chicago,IL. MDS 2001-13. Randomized, open-label, phase III trialof Decitabine (5-Aza-2’-Deoxycytidine) versus supportivecare in adults with advanced-stage myelodysplasticsyndromes. Contact: Laurie A. Lisak, MMS. Phone: 312-563-2535.
Rush-Presbyterian-St. Luke’s Medical Center, Chicago,IL. MDS 2002-02. Phase II trial to evaluate the efficacy ofTrisenox in patients with MDS, followed by thalidomide innon-responders. Eligible patients must belong to IPSS int 1or higher, have adequate hepatic and renal function asdefined by specific laboratory parameters, and have anECOG PS of 0–2. Patients will receive Trisenox alone for sixmonths. Patients who do not respond will have thalidomideadded to the regimen at 6 months. Contact: Laurie A.Lisak, MMS. Phone: 312-563-2535.
Rush-Presbyterian-St. Luke’s Medical Center, Chicago,IL. MDS 2000-08. Pilot Study to Test The Efficacy of Gleevec(STI 571) in Patients with Myelodysplastic Syndromes.Given the clinical and molecular similarities between CMLand CMMoL, especially those related to the activation oftyrosine kinase induced downstream events suggest thatsuppression of the same kinase in CMMoL by using anagent like Glivec may produce clinical benefit in theseindividuals. We propose to test this hypothesis by treatingone cohort of 15 CMMoL patients with Gleevec or STI571 at400 mg po daily. The second cohort of 15 patients [havingtranslocation (5;12)] will likewise receive Gleevec or STI571at 400 mg po daily. Response assessment will be madeevery 8 weeks and in case of disease progression, thepatient will be removed from the study. Responding patientsor those with stable disease will be treated for one year atleast with the drug provided by Novartis. After the one-yearperiod, further therapy will depend upon the discretion ofthe physician. Disease progression is defined asoccurrence of acute leukemia, increase in BM blasts by50% over pre-therapy values if the blast count was >5% tobegin with, and worsening cytopenia. Contact: Laurie A.Lisak, MMS. Phone: 312-563-2535.
Rush-Presbyterian-St. Luke’s Medical Center, Chicago,IL. MDS 2002-04. Pilot Study to Test the Efficacy of aCombination of Gleevec with Thalidomide in Patients withIdiopathic Primary Myelofibrosis, Myelofibrosis withMyeloid Metaplasia and Myelodysplastic Syndromes WhoPresent With Myelofibrosis. We propose to use acombination of thalidomide and Gleevec for the treatment ofpatients with MMM and MDS who present with Grade 3+
23
and greater myelofibrosis. The rationale for this combinationis that the anti-angiogenic and anti-TNF effects ofthalidomide may be potentiated by the anti-TGF-b, anti-PDGF effects of Gleevec to reduce marrow fibrosis in thisgroup of patients. We propose to treat 30 patients on thisstudy using Thalidomide starting at a dose of 100 mg perday and increasing to 400 mg per day and Gleevec at 600mg per day. Treatment will be continued for one year or untildisease progression. Bone marrows will be obtained at 16weeks and then at the end of the study. Contact: Laurie A.Lisak, MMS. Phone: 312-563-2535.
Rush-Presbyterian-St. Luke’s Medical Center, Chicago,IL. MDS2003-01. Pilot Study to Determine the ClinicalEfficacy of Coenzyme Q10 in Patients with MyelodysplasticSyndromes. We propose to treat 40 patients belonging toRA and or RARS or low risk and Int-1 categories of MDSpatients with CoQ10 at a starting dose of 300 mgescalating as tolerated to 1200 mg po qday. Patients willbegin taking 300 mg po BID with meals for Days 1–3. OnDays 4–6, patients will take 300 mg po TID with meals. OnDay 7 and onward, patients will take 300 mg po QID withmeals. Patients will be treated for up to a year unlessintolerable side effects and/or disease progression arenoted. Responses will be continuously evaluated by weeklyCBCs and bone marrows repeated every 16 weeks.Contact: Laurie A. Lisak, MMS. Phone: 312-563-2535.
Stanford University Medical Center, Stanford, CA. CTEP#2771. Safety and efficacy of bevacizumab: humanizedmonoclonal anti-VEGF antibody therapy for myelodysplasticsyndrome. Contact: Peter Greenberg, MD or Kathy Dugan,RN. Phone: 650-723-8594.
Stanford University, Stanford, CA. Study of DARBEPOETINALFA in Patients with MDS. Primary objectives are 1) toassess erythroid response to DARBEPOETIN ALFA, asdetermined by changes in hemoglobin and/or red bloodcell (RBC) transfusion-dependence. 2) to describe thesafety profile of DARBEPOEITN ALFA in patients with MDS.Contact: Sylvia Quesada, R.N. Phone: 650-725-4041.
Stanford University, Stanford, CA. Bevacizumab inTreating Patients With Myelodysplastic Syndrome. Multi-center trial with participating centers in Arizona, California,Texas. Contact: Sylvia Quesada, RN Phone: 650-725-4041.
St. Jude Children’s Research Hospital, Memphis, TN.DSAML. Treatment of children with down syndrome (DS)and acute myeloid leukemia (AML), myelodysplasticsyndrome (MDS), and transient myeloproliferative disorder(TMD). Contact: Nobuko Hijiya, MD. Phone: 901-495-3300.
St. Jude Children’s Research Hospital, Memphis, TN.AML02. Collaborative trial for the treatment of patients withnewly diagnosed acute myeloid leukemia or myelodysplasia.Contact: Jeffrey Rubnitz, MD, PhD. Phone: 901-495-3300.
St. Jude Children’s Research Hospital, Memphis, TN.HAPSCT. Phase III randomized trial to evaluate haplo-
identical stem cell transplantation utilizing purified CD34+hematopoietic cells for patients with hematologicmalignancies: a randomized study comparing positive andnegative selection methodologies. Contact: Gregory Hale,MD. Phone: 901-495-3300.
St. Jude Children’s Research Hospital, Memphis, TN.MUDSCT. Phase III controlled trial to evaluatehematopoietic stem cell transplantation for patients withhematologic malignancies: a comparison of T-celldepleted bone marrow with unmanipulated bone marrow.Contact: Edwin Horwitz, MD, PhD. Phone: 901-495-3300.
St. Jude Children’s Research Hospital, Memphis, TN.REFSCT. Pilot study to evaluate haploidentical stem celltransplantation utilizing T-Cell depletion as therapy forpatients with refractory hematological malignancies.Contact: Ely Benaim, MD. Phone: 901-495-3300.
Texas Oncology Medical City Dallas Hospital, Dallas,TX.D-0007. Randomized, open-label, Phase III trial ofdecitabine (5-aza-2’-deooxycytidine) versus supportivecare in adults with advanced-stage myelodysplasticsyndrome. This Phase III trial evaluates the efficacy ofdecitabine to treat MDS. Eligible patients may have denovo or secondary MDS. Growth factors (G-CSF,erythropoietin), steroids, hormones or chemotherapy fortreatment of MDS are not allowed for 2 weeks prior toenrollment. Contact: Craig Rosenfeld, MD. Phone: 972-566-7790.
Texas Oncology Medical City Dallas Hospital, Dallas,TX.SMC-101-1020. Open-label, prospective, stratified,randomized, controlled, multicenter, phase IIB study of theimpact of Thymoglobulin therapy on transfusion needs ofpatients with early myelodysplastic syndrome. This protocolevaluates Thymoglobulin therapy for 4 days. Eligibilityincludes low risk MDS (RA, RAEB <10%), IPSS <1.0,transfusion dependence, No prior chemotherapy allowed.Contact: Craig Rosenfeld, MD. Phone: 972-566-7790.
Texas Oncology Medical City Dallas Hospital, Dallas,TX. T-MDS-001. Multicenter, randomized, double-blind,placebo-controlled trial comparing best supportive careand thalidomide for the treatment of anemia in patientswith myelodysplastic syndrome followed by an open-label treatment with thalidomide. Recently, treatmentwith thalidomide has been reported to improve theanemia in some patients with MDS. The purpose of thisstudy is to further evaluate the effect of thalidomide orplacebo pills (50:50 chance) for 24 weeks. Thereafter, allsubjects can receive thalidomide for an additional 24weeks. The effect of treatment on transfusions andquality of life will be evaluated. Contact: CraigRosenfeld, MD. Phone: 972-566-7790.
University of Alabama at Birmingham ComprehensiveCancer Center, Birmingham, AL. Phase I/IIa Study of TLK199HCl Liposomes for injection in Myelodysplastic Syndromes.Contact: Peter Emanuel, MD. Phone: 205-975-2944.
University of Arizona Cancer Center, Tucson, AZ. HSC#02-11. Safety and efficacy trial of bevacizumab: anti-vegfhumanized monoclonal antibody therapy for MDS.Contact: Daruka Mahedevan, MD. Phone: 520-626-2340.
University of California at Los Angeles (UCLA) MedicalCenter, Los Angeles, CA. Randomized, multicenter,double-blind, placebo controlled trial assessing the safetyand efficacy of thalidomide (Thalidomid) for the treatmentof anemia in patients with myelodysplastic syndromes.Recently, treatment with thalidomide has been reported toimprove the anemia in some patients with MDS. Thepurpose of this study is to further evaluate the effect ofthalidomide or placebo pills (50:50 chance) for 24 weeks.Thereafter, all subjects can receive thalidomide for anadditional 24 weeks. The effect of treatment on transfusionsand quality of life will be evaluated. The most common sideeffects of thalidomide include severe birth defects,drowsiness, weakness, rash, shortness of breath, fluidretention, constipation, low blood pressure, decreasedwhite blood counts, slow heart beats and nerve damage.Contact: Ron Paquette, MD. Phone: 310- 825-5608.
University of Louisville, Louisville, KY. #541.02. Pilotstudy of arsenic trioxide and amifostine for the treatment ofmyelodysplastic syndromes. Eligible patients must have aconfirmed diagnosis of MDS. For patients with lower-riskonly: documented red blood cell dependence, defined asthe inability to maintain a hematocrit of >25% withouttransfusion support and patients with serum erythropoietinless than 200 IU/mL at screening should have failed torespond to a trial of recombinant erythropoietin (EPO)administered in accordance with institutional guidelines.Patients must have an ECOG PS 0-2 and adequate hepaticand renal function as evidenced by specific laboratorycriteria. Contact: R. Herzig, MD. Phone: 800-234-2689.
University of Michigan Comprehensive Cancer Center,Ann Arbor, MI. Phase II trial of combination therapy witharsenic trioxide (Trisenox) and gemtuzumab ozogamicin(Mylotarg) for the treatment of adult patients with advancedmyelodysplastic syndrome. Contact: Harry P. Erba, MD, PhD.
University of Pennsylvania Cancer Center, Philadelphia,PA. A pilot study of valproic acid in patients with MDS.Contact: Selina Luger, MD. Phone: 215-662-6348.
University of Pennsylvania Cancer Center, Philadelphia,PA. Pilot study of arsenic trioxide in patients with MDS.Contact: Selina Luger, MD. Phone: 215-662-6348.
University of Texas Health Science Center at SanAntonio, San Antonio, TX. Phase I/IIa Study of TLK199HCl Liposomes for injection in MyelodysplasticSyndromes. Contact: Natalie Callander, MD. Phone: 210-617-5300 Ext. 4720.
University of Texas Health Science Center at SanAntonio, San Antonio, TX. Randomized, double-blind,phase II study of the matrix metalloproteases inhibitor
Prinomastat in patients having myelodysplasticsyndromes. Eligible patients must be over 18 years of ageand have a diagnosis of MDS of at least 8 weeks duration,hemoglobin <9.0 g/dL (or be transfusion dependent) withadequate renal/hepatic function of serum creatinine lessthan or equal to 1.5 mg/dL and serum total bilirubin lessthan or equal to 2.0 mg/dL. Contact: Natalie Callander,MD. Phone: 210-567-4848.
University of Washington, Seattle, WA. UW-26-245-B.Phase I trial using subcutaneous, outpatient injection toevaluate the efficacy of Interleukin-2 to treat MDS. Eligiblepatients must have either refractory anemia, refractoryanemia with ringed sideroblasts, refractory anemia withexcess blasts, or chronic myelomonocytic leukemia; morethan 30 days since any prior treatment for MDS; Karnofskyperformance status >70; serum creatinine <2.0 mg/dL;bilirubin <1.6 mg/dL or SGOT <150. Contact: John A.Thompson, MD. Phone: 206-288-2015.
University of Wisconsin, Department of Medicine,Madison, WI. HO 02402. Phase I/II trial to evaluate theefficacy of Ontak (Denileukin Diftotox) for treating MDS.Participants must have no prior treatment with Ontak orATG and must be at least 18 years old. Contact: MarkJucket, MD. Phone: 608-263-1836.
University of Wisconsin, Department of Medicine,Madison, WI. HO 02403. Phase II trial usingDoxercalciferol (Vitamin D) for treating MDS. Participantsmust have no prior exposure to doxercalciferol and mustbe at least 18 years old. Contact: Mark Jucket, MD. Phone:608-263-1836.
Vanderbilt University Medical Center, Nashville, TN.Phase II study of arsenic trioxide in myelodysplasia.Contact: Shubhada M. Jagasia, MD. Phone: 615-322-4752.
Wake Forest University School of Medicine, Winston-Salem, NC. CCCWFU-29203. Orthomolecular Vitamin Din Low-Risk Myelodysplastic Syndrome: Phase II trialusing cholecalciferol (Vitamin D3) to evaluate the efficacyof 2000 IU Vitamin D3 daily for 6 months to treat MDS.Eligible patients must have MDS; IPSS score 0–1.0; lifeexpectancy >1 year; no other concurrent therapy forMDS; no history of hypercalcemia. Contact: IstvanMolnar, MD. Phone: 336-716-5847.
Washington University School of Medicine, St. Louis,MO. Multicenter, randomized, open-label, parallel-group,Phase 3 trial of subcutaneous azacitidine plus bestsupportive care versus conventional care regimens plusbest supportive care for the treatment of MyelodysplasticSyndromes (MDS). Contact: Alisa Ruddell. Phone: 314-454-4095.
Washington University School of Medicine, St. Louis,MO. This study seeks individuals with bone marrowfailure. Participants are asked to submit a sample ofblood for gene and telomere analysis. Researchers are
24
25
investigating the hTR gene found on chromosome 3.Participants are also asked to submit their medical andfamily history information. This information is used tomake correlations among the participants’ clinicalfeatures and the gene and telomere analysis. Contact:Jennifer Ivanovich, MS. Phone: 314-454-5076.
Western Pennsylvania Cancer Institute, Pittsburgh, PA.AZA PH GL 2003 CL 001. Multicenter randomized open-label parallel group phase IIl trial of subcutaneousazacitidine plus best supportive care versus conventionalcare regimens plus best supportive care for the treatmentof Myelodysplastic Syndromes (MDS). Contact: MichelleMarietti, RN. Phone: 412-578-5346.
European Trials
AUSTRALIA
The Newcastle Mater Miseriecordiae Hospital, NewSouth Wales. A multicenter randomized open-labelparallel group phase IIl trial of subcutaneous azacitidineplus best supportive care versus conventional careregimens plus best supportive care for the treatment ofMyelodysplastic Syndromes (MDS). Contact: Arno Enno.Phone: +61 2 4921 1215.
Princess Alexandra Hospital, Queensland. A multicenterrandomized open-label parallel group phase IIl trial ofsubcutaneous azacitidine plus best supportive careversus conventional care regimens plus best supportivecare for the treatment of Myelodysplastic Syndromes(MDS). Contact: Anthony Mills. Phone: +61 7 3240 2086.
Royal Adelaide Hospital, South Australia. A multicenterrandomized open-label parallel group phase IIl trial ofsubcutaneous azacitidine plus best supportive careversus conventional care regimens plus best supportivecare for the treatment of Myelodysplastic Syndromes(MDS). Contact: Noemi Horvath. Phone: +61 8 8222 3550.
The Alfred Hospital, Victoria. A multicenter randomizedopen-label parallel group phase IIl trial of subcutaneousazacitidine plus best supportive care versus conventionalcare regimens plus best supportive care for the treatmentof Myelodysplastic Syndromes (MDS). Contact: AndrewSpencer. Phone: +61 3 9276 3392.
The Royal Perth Hospital,Western Australia. A multicenterrandomized open-label parallel group phase IIl trial ofsubcutaneous azacitidine plus best supportive care versusconventional care regimens plus best supportive care forthe treatment of Myelodysplastic Syndromes (MDS).Contact: Richard Herrman, MD. Phone: +61 8 9224 2405.
ENGLAND
Kings College Hospital/Guys-Kings-Thomas School ofMedicine. Multi-center study of the role of 5-Azacitidine inhigh risk MDS. Contact: Professor Ghulam J. Mufti. Phone:44 (0) 207-346-3080.
Kings College Hospital/Guys-Kings-Thomas School ofMedicine. Randomized study of GCSF+Epo versussupportive care in low risk MDS. Contact: ProfessorGhulam J. Mufti. Phone: 44 (0) 207-346-3080.
The Royal Bournemouth Hospital. Multi-centre study ofthe role of 5-Azacytidine in high risk MDS (beginningSpring 2004). Contact: Sally Killick, MD. Phone: 44 (0)11202 704783.
The Royal Bournemouth Hospital. Multi-centre trial ofCEP-701 in older patients with AML. Contact: Sally Killick,MD. Phone: 44 (0) 11202 704783.
The Royal Bournemouth Hospital. Low dose antithymocyteglobulin in elderly patients with MDS and aplastic anaemia.Contact: Sally Killick, MD. Phone: 44 (0) 11202 704783.
FRANCE
Institute Paoli Calmettes, Marseilles. Phase I/II multi-center study of arsenic trioxide in patients with MDS.Contact: Norbert Vey, MD. Phone: +33 4 91223695.
Institute Paoli Calmettes, Marseilles. A multicenterrandomized open-label parallel group phase IIl trial ofsubcutaneous azacitidine plus best supportive careversus conventional care regimens plus best supportivecare for the treatment of Myelodysplastic Syndromes(MDS). Contact: Norbert Vey, MD. Phone: +33 4 91223695.
Hopital Beaujon, Clichy. A multicenter randomized open-label parallel group phase IIl trial of subcutaneousazacitidine plus best supportive care versus conventionalcare regimens plus best supportive care for the treatmentof Myelodysplastic Syndromes (MDS). Contact: PierreFenaux, MD. Phone: +33 1 40874522.
Chu Purpan, Toulouse. A multicenter randomized open-label parallel group phase IIl trial of subcutaneousazacitidine plus best supportive care versus conventionalcare regimens plus best supportive care for the treatmentof Myelodysplastic Syndromes (MDS). Contact: GuyLaurent, MD. Phone: +33 5 61772078.
Chu De Nantes, Nantes. A multicenter randomized open-label parallel group phase IIl trial of subcutaneousazacitidine plus best supportive care versus conventionalcare regimens plus best supportive care for the treatmentof Myelodysplastic Syndromes (MDS). Contact: BeatriceMahe, MD. Phone: +33 2 40083252.
Che De Lille, Lille. A multicenter randomized open-labelparallel group phase IIl trial of subcutaneous azacitidineplus best supportive care versus conventional careregimens plus best supportive care for the treatment ofMyelodysplastic Syndromes (MDS). Contact: BrunoQuesnel, MD. Phone: +33 3 20446640.
Hopital Cochin, Paris. A multicenter randomized open-label parallel group phase IIl trial of subcutaneousazacitidine plus best supportive care versus conventional
26
care regimens plus best supportive care for the treatmentof Myelodysplastic Syndromes (MDS). Contact: FrancoisDreyfus, MD. Phone: +33 1 58412120.
GERMANY
Heinrich-Heine University Dusseldorf. A multicenterrandomized open-label parallel group phase IIl trial ofsubcutaneous azacitidine plus best supportive careversus conventional care regimens plus best supportivecare for the treatment of Myelodysplastic Syndromes(MDS). Contact: Norbert Gattermann, MD. Phone: +49 211811 6500.
University Hospital Frankfort/Main. AntithymocyteGlobulin (ATG) and Cyclosporine (CSA) to Treat Patientswith Myelodysplastic Syndromes. A randomized trialcomparing ATG+CSA with best supportive care AmendedProtocol SAKK 33/99. Contact: Wolf-K. Hofmann, MD.Phone: +49-69-6301-4802.
University Hospital Frankfort/Main. Phase II Study withThalidomide in patients with myelodysplastic syndromes.Contact: Wolf-K. Hofmann, MD. Phone: +49-69-6301-4802.
University Hospital Frankfort/Main. LAQ824 (inhibitor ofhistone-deacetylase) in patients with relapsed/refractoryAML, advanced CLL, CML in blast crisis or advancedMDS. Contact: Wolf-K. Hofmann, MD. Phone: +49-69-6301-4802.
University Hospital Freiburg. Phase II study of low-doseintravenous decitabine in patients aged >60 years withacute myeloid leukemia who are not eligible for standardinduction chemotherapy. Contact: Michael Lübbert, MD,PhD. Phone: +49-761-270-3279.
University Hospital Freiburg. Intravenous low-dosedecitabine versus supportive care in elderly patients withprimary Myelodysplastic Syndrome (MDS) (>10% blasts orhigh-risk cytogenetics), secondary MDS or ChronicMyelomonocytic Leukemia (CMML) who are not eligible forintensive therapy: an EORTC-German MDS Study Grouprandomized Phase III study. Contact: Michael Lübbert,MD, PhD. Phone: +49-761-270-3279.
University Hospital Hamburg. Allogeneic stem celltransplantation after toxicity-reduced conditioning regimenwith treosulfan and fludarabine for patients with MDS orsAML, who were not eligible for a standard conditioningregimen: a phase II study. Contact: Nicolaus Kröger, MD.Phone: +49-40-42803-4851.
University Hospital Hamburg. Dose-reduced versusstandard conditioning followed by allogeneic stem celltransplantation in patients with MDS or sAML. Arandomized phase III study (May 2004). Contact: NicolausKröger, MD. Phone: +49-40-42803-4851.
HUNGARY
Semmelweis University School of Medicine, Budapest.Investigation of the multifactorial cause of iron overloadby testing HFE gene mutations: C282Y and H63D,determination of copper and coeruloplasmin level, analysisof transferring receptor mutation and also TNF-alphapromoter gene polymorphism in MDS patients. Contact:Judit Varkonyi, MD, PhD. Phone/Fax: 361-355-8251.
ITALY
Unit of Hematology and Stem Cell Transplantation,IRCCS “Casa Sollievo della Sofferenza” Hospital. APhase III clinical trial comparing a single, weekly dose ofrecombinant erythropoietin alpha (40.000 units) aloneversus the combination of this treatment plus low-dosethalidomide for anemic, low-risk MDS. Contact: Dr.Pellegrino Musto. Phone: 39 (0) 882-410295-539.
Unit of Hematology and Stem Cell Transplantation,IRCCS “Casa Sollievo della Sofferenza” Hospital. APhase I/II clinical evaluating the effect of long-actingerythropoietin darboepoietin-alpha in low-risk, anemicMDS. Contact: Dr. Pellegrino Musto. Phone: 39 (0) 882-410295-539.
Unit of Hematology and Stem Cell Transplantation,IRCCS “Casa Sollievo della Sofferenza” Hospital. APhase I/II clinical study on allogenic “conventional” and“mini” (non-myelosuppressive) peripheral blood stem celltransplantation in patients with high risk MDS. Contact: Dr.Pellegrino Musto. Phone: 39 (0) 882-410295-539.
POLAND
Jagiellonian University, Cracow. A randomized trialcomparing Antithymocyte Globulin (ATG) andCyclosporine (CSA) with best supportive care in patientswith MDS. Contact: Prof. Aleksander B. Skotnicki, MD.Phone: +48-12-421-3693.
Jagiellonian University, Cracow. Phase I/II study ofThalidomide in low-risk MDS. Contact: Pawel Sledziowski,MD. Phone: +48-12-424-7600.
Jagiellonian University, Cracow. Phase III clinical trial ofAmifostine/pentoxifylline/ciprofloxacin/dexamethasonefor low-risk MDS. Contact: Janusz Krawczyk, MD. Phone:+48-12-424-7600.
Jagiellonian University, Cracow. Phase I/II study ofArsenic Trioxide in high-risk MDS. Contact: MarcinSobocinski, MD. Phone: +48-12-424-7600.
THE NORDIC COUNTRIES
Nordic MDS Group. Maintenance treatment with 5-azacytidine in patients with advanced MDS and MDS-AML,who have obtained CR with intensive chemotherapy. Anopen perspective Phase II study M\NMDSG02B. Contact:
27
To submit information onyour clinical trials for publication,
you can fax (609-298-0590)us at the Foundation.
Please include a contact person,a phone number, and if applicable,
the trial number.
Be a BoneMarrow DonorFor those patients diagnosed with a fatal blooddisorder, bone marrow transplantation (BMT) is oftenthe only chance of survival. Related donors providesuitable matches only 33 percent of the time. Thisleaves nearly 70 percent of patients without a match.The need is especially critical in racial and ethnicminority groups.
Registering as a donor is simple. A blood sampleis all you need to enter your tissue type into theNational Marrow Donor Program (NMDP) computerizedregistry. If you are in good health and between the ages of 18 and 55, you can contact NMDP at 1-800-MARROW-2. They will send additionalinformation, including the NMDP center nearest you.
Give the Gift of Life!
OTHER SITES OF INTEREST:ASBMT™ American Society forBlood and Marrow Transplantation: www.asbmt.org
International Bone Marrow Transplant Registry:www.isbmtr.org
National Marrow Donor Program®:www.marrow.org
Blood & Marrow Transplant Information Network:www.bmtinfonet.org
Eva Hellström-Lindberg, MD, PhD. Phone: 011-46-85-858-0000.
Nordic MDS Group. Effects of anemia in MDS quality oflife, cardiac function and health care costs. An open, non-randomized Phase II study NMDSG03A. Planned to startApril 2004. Contact: Herman Nilsson-Ehle. Phone: 011-46-85-858-0000.
SPAIN
Hospital Clinic, Barcelona. A multicenter randomizedopen-label parallel group phase IIl trial of subcutaneousazacitidine plus best supportive care versus conventionalcare regimens plus best supportive care for the treatmentof Myelodysplastic Syndromes (MDS). Contact: BenetNomdedeu, MD. Phone: +34 93 227 55 11.
Hospital Son Llatzer, Palma de Mallorca. Amulticenter randomized open-label parallel groupphase IIl trial of subcutaneous azacitidine plus bestsupportive care versus conventional care regimensplus best supportive care for the treatment ofMyelodysplastic Syndromes (MDS). Contact: JoanBargay, MD. Phone: +34 871 20 21 38.
Hospital Universitario Del Salamanca, Salamanca. Amulticenter randomized open-label parallel group phase IIltrial of subcutaneous azacitidine plus best supportivecare versus conventional care regimens plus bestsupportive care for the treatment of MyelodysplasticSyndromes (MDS). Contact: Consuelo Del Canizo, MD.Phone: +34 923 29 13 84.
An Update:The MDS Foundation will soon be working with theEuropean Hematology Association’s MDS Working Group(EHA) to standardize information on clinical trials inEurope. This will aid physicians and patients in identifyingand contacting centers about participating in these trials.We’ll keep you up to date!
Inaugural MDSFoundation CharityGolf Tournamentis a Huge SuccessThe MDS Foundation hosted its Inaugural CharityGolf Tournament on Monday, August 9th at OldeYork Country Club in Chesterfield, NJ. Thank youto everyone who participated in this worthwhileevent, the proceeds of which will benefit supportand education in the myelodysplastic syndromesfor physicians and patients. For more details,look for our upcoming Fall Edition of The MDSNews and don’t forget to save the date for nextyear: Monday, August 1, 2005!
28
In MemoriumA memorial fund has been established in the name of
Mr. John AnderholmDonations have been made in Mr. Anderholm’s memory by:
Hazel Marie Anderholm, Walnut Creek, CA
A memorial fund has been established in the name of
Mrs. Alice HenegarDonations have been made in Mrs. Henegar’s memory by:
Raymond and Donna Brodie, Rossville, GA
A memorial fund has been established in the name of
Mrs. JonesDonations have been made in Mrs. Jones’ memory by:
Tim and Franca Grima, Vancouver, BC
A memorial fund has been established in the name of
Mr. Joseph KotelnickiDonations have been made in Mr. Kotelnicki’s memory by:
Tammy and Michael Kotelnicki, Vienna, VAA memorial fund has been established in the name of
Mr. James B. CorcoranDonations have been made in Mr. Corcoran’s memory by:
Reno Dental Associates, Reno, NV
Roy and Ardis AllenEllsworth, MEHelen C. PhillipsOrlando, FLBeverly AllenKoloa, HI
John DillardHarvard, MABlair and Sandra IngallsFranklin, ME
A memorial fund has been established in the name of
Mr. George AllenDonations have been made in Mr. Allen’s memory by:
James and Ruthie OlsonGrand Rapids, MN
Rick Schwab, Minneapolis, MNStar Tribune, Minneapolis, MN
A memorial fund has been established in the name of
Mrs. Mary Lou EekhoffDonations have been made in Mrs. Eekhoff’s memory by:
Brenda K. PetersMilford, MI
Pauline CantyWhite Lake, MI
A memorial fund has been established in the name of
Mrs. Christine GieckelDonations have been made in Mrs. Gieckel’s memory by:
Natalie GordonOceanside, NYJoel and Maureen RothsteinParamus, NJDana Quint SopherCloster, NJSelma HudesmanWoodmere, NYJacob and Bonnie GorenCliffside Park, NJ
Robert and Betty CohenCheltenham, PADaniel and Leila AlexanderNew York, NYFeldman FamilyPaterson, NJBruce and Renee LiversLake Worth, FLMorris and Ann SchefflerValley Stream, NY
A memorial fund has been established in the name of
Dr. Joseph GuttfriendDonations have been made in Dr. Guttfriend’s memory by:
John M. Hammitt, Jr.Sea Bright, NJJohn R. BarbanoCranbury, NJ
Joseph and Dawn MoorconesSkillman, NJGeraldine BenningtonParlin, NJ
A memorial fund has been established in the name of
Mr. John M. HammittDonations have been made in Mr. Hammitt’s memory by:
Mary H. WestfallColusa, CAJoan DanforthSan Francisco, CAAndy and Sharon SillerYuba City, CAJack and Marie TedsenCrescent City, CAM.D. Lee and P. PoonSan Lorenzo, CAJudi and Gil BartonRocklin, CAMelvin and Linda ArantColusa, CA
Violet WescottColusa, CARita and Gar RourkeColusa, CAG.C. RourkeColusa, CASeeds By DesignMaxwell, CAJack and Marie TedsenCrescent City, CASigrid V. Lenert, MDSacramento, CAJoyce A. Carlson, RNSacramento, CA
A memorial fund has been established in the name of
Mrs. Florence LittlejohnDonations have been made in Mrs. Littlejohn’s memory by:
Caroline WagnerNewtown, PALeroy and Theresa AlexanderPenndel, PA
Raymond and Helen DelfingLevittown, PAJean DelfingLevittown, PA
A memorial fund has been established in the name of
Mr. Michael ArlenDonations have been made in Mr. Arlen’s memory by:
Paul and Brenda JaffeChappaqua, NYSpringfield Little TheatreSpringfield, MOHarold and Leah WeeresColorado Springs, CO
Walter and Joan MorganThornwood, NYFrank and Colette LaicoSomers, NYLinda MayberryRepublic, MO
A memorial fund has been established in the name of
Mr. Ward BotsfordDonations have been made in Mr. Botsford’s memory by:
Ralph and Elaine LimhoffBalboa, CARichard JonesNewport Beach, CACharles and Barbara StrodelCorona Del Mar, CA
Patricia ZornCorona Del Mar, CAPreston and Bonnie ZillgittCorona Del Mar, CA
A memorial fund has been established in the name of
Mr. John CazierDonations have been made in Mr. Cazier’s memory by:
James and Joan CraneHilton Head Island, SCRolf and Nora MarshallHuntington, NYMargaret LampmanHilton Head Island, SCGail GronbachGrunlawn, NYRuth Kiefer Hilton Head Island, SC
John and Faye PeterkenMarietta, GAMary Louis RossMiddletown, CTMarjorie CoughlinMiddletown, CTNancy Jane AllenN. Kingstown, RI
A memorial fund has been established in the name of
Mr. Warren DemingDonations have been made in Mr. Deming’s memory by:
A memorial fund has been established in the name of
Mr. Alan MarcusDonations have been made in Mr. Marcus’ memory by:
Gary, Adelle, and Arlene Rothstein, Phoenix, AZ
29
A memorial fund has been established in the name of
Mrs. Shirley MillardDonations have been made in Mrs. Millard’s memory by:
Glenn Millard, Whitewater, WI
A memorial fund has been established in the name of
Dr. Alan James PetersonDonations have been made in Dr. Peterson’s memory by:
Gosta and Mary Iwasiuk, Santa Paula, CA
Mark and Jeanette HalRye, NYWilliam and Lorraine StrachanRedford, MICynthia RedrupToledo, OHDavid and Kathleen WojcikShamong, NJGrace MilitzerKalamazoo, MIThomas and Joyce MartinPerkasie, PANorman and Nancy MahrleyBrighton, MIMichael and Theresa WaldenQueenstown, MDGloria KashmerickRochester, MI
Cosmo and Robin MellusiWestfield, NJJohn and Mary KillionPhiladelphia, PACynthia KillionPhiladelphia, PARobert PeacockMurray Hill, NJNorman D. NassonBelle Haven, VAMichael and Eloise NaylorMoorestown, NJChristine MorrisseyEmmaus, PAEvensonBest LLCNew York, NY
A memorial fund has been established in the name of
Mrs. Virginia MilitzerDonations have been made in Mrs. Militzer’s memory by:
Ed and Ernestine NortonBrookhaven, MSAnn B. HearinPoint Clear, ALDonald and Melissa JonesHouston, TX
Helen KellyTerre Haute, INMr. and Mrs. William J. ReedTerre Haute, INBen and Phyllis SpearmanBrookhaven, MS
A memorial fund has been established in the name of
Mrs. Janet MullikinDonations have been made in Mrs. Mullikin’s memory by:
Steven and Joleen SteinGypsum, KSCarolyn NaughtonLakewood, COLois S. BarnesDenver, COSheabeen PubAurora, COKaren ZiereisLakewood, CO
Robert and Deborah WeinerGreenwood Village, COCynthia and Betty WestPhoenix, AZDr. and Mrs. Robert L. WeineGreenwood Village, COIrene MyersLakewood, COGeorge and Catherine HoerterLakewood, CO
A memorial fund has been established in the name of
Dr. Michael NaughtonDonations have been made in Dr. Naughton’s memory by:
Mary E. A. AllbeeMarlton, NJGeorge and Lois ReamLancaster, PALittle Mill Country Club, Inc.Marlton, NJClinton and Suzanne MillerMedford Lakes, NJChristian R. McDanielHaslett, MIClinton County Counseling CenterSt. Johns, MIJohn J. and Mary Lynn GallagherVoorhees, NJColetta BergerCinnaminson, NJBette BanksMarlton, NJFrederick O’NeilMarlton, NJWilliam T. De Van, Jr.Marlton, NJ
B. HillsHaddon Township, NJWalter and Dolores HaworthBurlington, NJGeorge and Regina SpeckWest Berlin, NJETEA Philanthropic FundMarlton, NJRonald and Ellen KerstetterMedford Lakes, NJPAR Rehab ServicesLansing, MIJulia DonahueGlendors, NJRoger and Grace RhynerSomerdale, NJArnold GordonMarlton, NJDr. and Mrs. Richard E. SchwartzMarlton, NJ
A memorial fund has been established in the name of
Mrs. Barbara Claire MelandDonations have been made in Mrs. Meland’s memory by:
Robert and Renee HillMarengo, ILJanis St. GeorgeSchaumburg, ILCarolyn DowdingDelavan, WIHenry and Joan Van DiggelenFontana, WI
Robert and Yevonne ReedCumberland, RIRobert and Cynthia BroganSleepy Hollow, ILRichard and Shirley JonesDelavan, WIKaren SimaNorthlake, IL
A memorial fund has been established in the name of
Mr. William H. ReicholdDonations have been made in Mr. Reichold’s memory by:
Gregory PeterChelsea, MI Larry and Sandy AtwellGibsonton, FLLibby DeMarioBoynton Beach, FLDennis and Jeanette GrabowskiMacomb, MIAunt LibbyMacomb, MIRonald and Judy PeplowskiWaterford Township, MISusan and Kyle RothwellStamford, CTJohn and Mary HarmonGrand Island, FLDouglas and June AllenGrand Island, FLHenry and Marcella WojtowiczJohannesburg, MIMichael and Claudine ButtsTerre Haute, ING. Stanley and Marilyn HareGrand Island, FLWilliam and Margery SandbergGrand Island, FLDoris M. GoldyGrand Island, FLRonald and Barbara HackbarthGrand Island, FLWilliam and Evelyn SchultzGrand Island, FLKathleen L. ArnettGrand Island, FLGarland and Rita HelmingGrand Island, FLMarylyn D. CopeGrand Island, FLLeonard and Joyce GriffithGrand Island, FLBurton and Mildred HeistGrand Island, FL
Thomas and Ann HilliardGrand Island, FLDonald and Kathleen BongioviGrand Island, FLRandall and Jacqueline R. JoubertGrand Island, FLWayne F. HaganGrand Island, FLPeggie F. PilkerGrand Island, FLStephen and Shirley ParkGrand Island, FLJohn and Marianne PrzyuskiGrand Island, FLCarl and Beth CrullGrand Island, FLSidney and Mary Jane WiedrickMiddlesex, NYGerald and Barbara HosenfeldWebster, NYJames and Shirley MarshGrand Island, FLRichard J. WdowiakLady Lake, FLDaniel and Catherine MorleyGrand Island, FLRuth L. KlugSummerfield, FLMr. and Mrs. B. Rex ReininkTipton, MIJoe and Lynn BauerDundee, MIRandy and Lauri FreckeltonEastpointe, MIRobert and Carol BalcerzaHarrison Township, MIGrand View Farm, Inc.Hammondsport, NYSunlake Social ClubIrwin and Betty Jurs
A memorial fund has been established in the name of
Mrs. Roberta McIntyreDonations have been made in Mrs. McIntyre’s memory by:
30
Patient ServicesAirLifeLine: For nearly 25 years, AirLifeLine hashelped people overcome the obstacle of distanceand access to healthcare. Through a nationwidenetwork of 1,500 volunteer pilots, AirLifeLinecoordinates free air transportation for people in need.AirLifeLine’s generous and compassionate volunteerpilots—men and women from all 50 states with awide variety of backgrounds—donate flights in theirpersonal general aviation aircraft. Passengers flytotally free, as often as necessary and for as long asneeded, to reach medical care or for numerous otherhumanitarian needs. Since 1978, and AirLifeLinevolunteer pilots have flown over 30,000 missions. In 2002, AirLifeLine volunteer pilots provided free air transportation for nearly 9,500 passengers (men,women, and children), saving them over $4 million incommercial travel expenses, helping them reachmedical treatment that would otherwise be inaccessible.
Although the vast majority of its passengers fly formedical reasons, AirLifeLine pilots also offer freeflights for other humanitarian reasons. Each summer,AirLifeLine’s volunteer pilots distribute the childrenfrom Chernobyl to host homes across the U.S. for a two-month summer respite. They also transporthundreds of children to health-related summer campseach year. And, within 48 hours of the terrorist attackson 9/11/01 and while most aircraft were still grounded,AirLifeLine volunteer pilots were in the air transportingemergency service personnel, disaster victims, bloodand medical supplies in support of disaster reliefefforts in New York City and Washington, D.C.
AirLifeLine is a non-profit 501 (c) (3) organizationthat relies 100% on the generosity of volunteer pilots,as well as individual, corporate, and foundationcontributions. AirLifeLine is the oldest and largestnational volunteer pilot organization in the UnitedStates. For more information about AirLifeLine, visitwww.AirLifeLine.org or call toll-free (877) AIR LIFE(877-247-5433).
RESOURCE DATABASE INFORMATION:
Agency Name: AirLifeLine
National Office5775 Wayzata Blvd., Suite 700Minneapolis, MN 55416
Phone: (952) 582-2980Toll-free: (877) 727-7728Fax: (952) 546-5885
A memorial fund has been established in the name of
Mr. Francis SeikerDonations have been made in Mr. Seiker’s memory by:
Marilyn SeikerOmaha, NE
A memorial fund has been established in the name of
Mr. Aaron WegweiserDonations have been made in Mr. Wegweiser’s memory by:
Beatrice WegweiserPlantation, FL
Ernest and Edith NiedererHoney Creek, WI CH2MHILLMilwaukee, WIPat and Josephine DalessandroOak Brook, IL
Mr. and Mrs. Thomas HirtleDelavan, WIArne and Jennine FloloW. Chicago, ILPlumbers and Pipefitters Local 501Aurora, IL
Mr. William H. Reichold (continued)
John and Anna CoronaRocky Hill, CTRoberta J. ParrottThe Villages, FLJoseph and Pat GulinoEast Hampton, CTIvette Kuczenski & CoworkersHartford, CT
Peter and Jann DymerskiEnfield, CTRobert and Noella LapierreNewington, CTAJ Bafundo & Co. LLCNewington, CT
A memorial fund has been established in the name of
Mrs. Norma RolandoDonations have been made in Mrs. Rolando’s memory by:
Joan ValicentiOrleans, MA
Mr. and Mrs. John DeeganBrewster, MA
A memorial fund has been established in the name of
Mr. Richard ValicentiDonations have been made in Mr. Valicenti’s memory by:
Thank You to OurPharmaceuticalPartnersWe would like to thank our pharmaceuticalpartners for their support of the Foundationand its work. They have contributed in theform of unrestricted educational grants, whichsupport not only this newsletter but also thedevelopment of the MDS home page on theWorld Wide Web, the Centers of Excellenceprogram, continuing medical educationprograms, the Patient Registry, and thedissemination of patient information.
Call here for: Outreach, development andadministrative inquiries.
Operations Center50 Fullerton Ct.Suite 200 Sacramento, CA 95825
Phone: (916) 641-7800Toll-free: (877) AIR LIFE (247-5433)Fax: (916) 641-0600Call here for: Passenger/pilot inquiries
TYY: Not available, but we can use a relay operator.
Website: www.AirLifeLine.org
E-mail: [email protected]
Administrator: Randy Quast, President & Volunteer Pilot
Contact Person for Agency Information:Ginger BuxaDirector of [email protected](877) 727-7728
Program Description:Since 1978, AirLifeLine has helped to ensure equalaccess to healthcare and improve the quality of lifefor thousands of people throughout the UnitedStates by coordinating free air transportation forthose in need.
Services Provided:AirLifeLine coordinates the following services:
1. Transporting people with medical and financialneed to reach medical care far from home.
2. Transporting people with time-critical needsassociated with a transplant procedure.
3. Transporting precious cargo such as organs,blood, tissue and medical supplies.
4. Providing free air support for disaster relief effortsin times of crisis.
5. Providing flights for numerous other humanitarian needs.
Funding Source:AirLifeLine is a national non-profit 501(c)(3),charitable organization funded entirely by taxdeductible donations from individuals, foundationsand corporations and the generosity of our volunteerpilots who donate the direct costs of every flight.Over 94% of all support and contributions donatedto AirLifeLine goes directly to program services.
31
Volunteer Opportunities:AirLifeLine is currently seeking volunteer pilots inmany areas of the country. For more information,visit www.AirLifeLine.org or call (877) AIR LIFE.
Passenger Eligibility:Our volunteer pilots fly passengers free of chargeand as often as necessary for diagnosis, treatment,and follow-up care, and for other humanitarianreasons.
1. AirLifeLine passengers must be ambulatory orneed little or no assistance to board and exit the aircraft.
2. Passengers must be medically stable and able tofly in an unpressurized aircraft.
3. Passengers must demonstrate financial need.
Application Method:To request a free flight, just call toll-free(877) AIR-LIFE (877-247-5433). In urgent situations,a coordinator can be paged after normal businesshours. Just call (877) AIR LIFE and follow thepaging instructions on the voice mail message.
You may also request a flight by visitingwww.AirLifeLine.org.
Service Area:All U.S. states, parts of Canada and Mexico.
Cost/Fees:None, but donations accepted.
Waiting List:None, but 1–2 weeks advance notice is preferred.
Target Group:Anyone with financial need who needs airtransportation.
Age Range: All
Handicap Access:Somewhat, depending on type and sizeof aircraft.
Languages:English and Spanish
If you need more information for your resourcedatabase or website listing, please contact:Ginger BuxaDirector of Outreach(877) 727-7728, E-Mail: [email protected]
32
Gifts to the FoundationThe MDS Foundation relies entirely on gifts andmembership fees to further its work. We would like to acknowledge the generosity of the followingindividuals and organizations that have recentlyprovided gifts to the Foundation:
United Way of New York City on behalf of Susan J. FerberNew York, NY
Virginia Klimek, MDMemorial Sloan-Kettering Cancer CenterNew York, NY
James W. Hester, Lilburn, GA
Robert and Donna Vieraitis, Los Altos, CA
New Prairie Junior High School New Carlisle, IN
David and Cheryl SeltzerLos Altos, CA
Geoffrey and Sandy GoldwormCherry Hill, NJ
The MDS Foundation is very grateful for theheartfelt support of its donors. Our work as a non-profit organization depends on public funding. If you would like to contribute or if you have aunique idea of your own, please write to us at:
36 Front Street, PO Box 353Crosswicks, NJ 08515 or call us at 1-800-MDS-0839
MDS Board of DirectorsJohn M. Bennett, MDProfessor of Oncology in Medicine,Pathology, and Laboratory Medicine
University of RochesterRochester, New York, U.S.A.
David T. Bowen, MDUniversity of Dundee Medical SchoolDundee Teaching HospitalDundee, Scotland
Theo J.M. de Witte, MD, PhDUniversity of NijmegenUniversity Hospital St. RadboudNijmegen, The Netherlands
Peter L. Greenberg, MDProfessor of Medicine/HematologyStanford University School of MedicineStanford, California, U.S.A.
Terry Hamblin, DM, FRCP, FRC PathProfessor of ImmunohaematologySouthampton UniversityBournemouth, England, U.K.
Eva Hellstrom-Lindberg, MD, PhDKarolinska InstitutetInstitution for MedicineHuddinge University HospitalStockholm, Sweden
Kathy Heptinstall, BSN, RNOperating DirectorThe MDS Foundation
Alan F. List, MDProfessor of MedicineUniversity of South FloridaTampa, Florida, U.S.A.
G.J. Mufti, MDProfessor of MedicineSchool of Medicine and Dentistry ofKing’s College London
London, England, U.K.
Charlotte M. Niemeyer, MDProfessor of PediatricsUniversity Children’s HospitalFreiburg, Germany
Stephen D. Nimer, MDMemorial Sloan-KetteringCancer Center
New York, New York, U.S.A.
Hussain I. Saba, MD, PhDProfessor of MedicineUniversity of South FloridaTampa, Florida, U.S.A.
Franz Schmalzl, MDProfessor, Department of Internal MedicineUniversity Hospital of InnsbruckInnsbruck, Austria
Robert J. Weinberg, Esq.Pepper Hamilton LLPPhiladelphia, Pennsylvania, U.S.A.
Apotex Inc. has provided theMDS Foundation with unrestricted educational
grants to support the Foundation’s work.
